Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.69 - Protein C (activated)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Cross-comparison of the genome sequences from human, chimpanzee, Neanderthal and a Denisovan hominin identifies novel potentially compensated mutations.
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage.
Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR.
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.
Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors.
Prevalence of activated protein C resistance among women with recurrent miscarriage.
Primary recurrent miscarriages: anti-beta2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test.
Abortion, Spontaneous
Activated protein C resistance and adverse pregnancy outcome.
Are women with polycystic ovary syndrome resistant to activated protein C?
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance.
Second-trimester pregnancy loss is associated with activated C resistance.
The factor V Leiden mutation is not a common cause of recurrent miscarriage.
[Recurrent miscarriage or failed in-vitro fertilization: antibodies against annexin V, cardiolipin, beta-2-glycoprotein-1 and APC-resistance]
[Study on relationship of activated protein C resistance and recurrent spontaneous abortion]
Abruptio Placentae
Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption.
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae.
Single inherited thrombophilias and adverse pregnancy outcomes.
The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.
Thrombophilias and pregnancy complications: a case-control study.
Abscess
Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
[Severe sepsis as a complication of descending necrozing mediastinitis due to a peritonsillar abscess. A case study]
Acquired Immunodeficiency Syndrome
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
Activated Protein C Resistance
"ProC Global": a functional screening test that predicts recurrent venous thromboembolism.
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms.
A case series of 72 neonates with renal vein thrombosis. Data from the 1-800-NO-CLOTS Registry.
A chromogenic assay for activated protein C resistance.
A clinical audit of congenital thrombophilia investigation in tertiary practice.
A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability.
A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.
A fast and robust dual-label nonradioactive oligonucleotide ligation assay for detection of factor V Leiden.
A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.
A hemi-nested, allele specific, whole blood PCR assay for the detection of the factor V Leiden mutation.
A highly specific functional test for factor V leiden: A modified tissue factor assay for activated protein C resistance.
A modified functional global test to measure protein C, protein S activities and the activated protein C-resistance phenotype.
A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network.
A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with a lupus anticoagulant.
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.
A Novel Mutation (G2172-->C) in the Factor V Gene in a Chinese Family with Hereditary Activated Protein C Resistance.
A novel mutation of Arg306 of factor V gene in Hong Kong Chinese.
A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure.
A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance.
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
A role for "acquired" activated protein C resistance in recurrent fetal loss?
A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies.
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
Acquired activated protein C resistance caused by lupus anticoagulants.
Acquired activated protein C resistance in myeloma patients with venous thromboembolic events.
Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels.
Acquired activated protein C resistance in pregnancy is not due to elevated plasma caeruloplasmin levels.
Acquired activated protein C resistance in pregnancy.
Acquired activated protein C resistance in sarcoma patients.
Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus.
Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Acquired activated protein C resistance may be a risk factor for recurrent fetal loss.
Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus.
Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an irish cohort of pregnant women.
Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis.
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Acquired resistance to activated protein C in breast cancer patients.
Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
Activated protein C resistance (APCR) and placental fibrin deposition.
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states.
Activated protein C resistance (FV:Q506) and pregnancy.
Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis.
Activated protein C resistance acquired through liver transplantation.
Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Activated protein C resistance and adverse pregnancy outcome.
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
Activated protein C resistance and antiphospholipid antibodies in recurrent fetal loss: experience of a single referral center in northern iraq.
Activated protein C resistance and deficiencies of antithrombin III, protein C or protein S and the risk of thromboembolic disease in users of oral contraceptives.
Activated protein C resistance and factor V Leiden in Mexico.
Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome.
Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis.
Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.
Activated protein C resistance and factor V Leiden: a review.
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Activated protein C resistance and graft occlusion after coronary artery bypass surgery.
Activated protein C resistance and inherited thrombosis.
Activated protein C resistance and its correlation with thrombophlebitis in Behçet's disease.
Activated protein C resistance and Japanese NIDDM patients with coronary heart disease.
Activated protein C resistance and low molecular weight lipoprotein (a): dual pathogens for atherothrombosis?
Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
Activated protein C resistance and lupus anticoagulant in pregnancy.
Activated protein C resistance and myocardial infarction.
Activated protein C resistance and pregnancy complications.
Activated protein C resistance and pregnancy loss.
Activated protein C resistance and Sneddon's syndrome.
Activated protein C resistance and the factor V Leiden mutation in children with thrombosis.
Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
Activated protein C resistance and thrombosis.
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Activated protein C resistance as a "new" cause of deep venous thrombosis in aviators.
Activated protein C resistance as a basis for venous thrombosis.
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Activated protein C resistance assay and factor V Leiden.
Activated protein C resistance assay as a screening test for thromboembolic disposition.
Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
Activated protein C resistance assay when applied in the general population.
Activated protein C resistance associated with lupus anticoagulants is a high risk in acute mesenteric venous thrombosis.
Activated protein C resistance associated with maternal floor infarction treated with low-molecular-weight heparin.
Activated protein C resistance can be associated with recurrent fetal loss.
Activated protein C resistance caused by a common factor V mutation has a single origin.
Activated protein C resistance caused by Arg506Gln mutation in factor Va.
Activated protein C resistance caused by factor V Arg 506-->Gln mutation has no role in thrombotic manifestations of Behçet's disease.
Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants.
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients.
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.
Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Activated protein C resistance during in vitro fertilization treatment.
Activated protein C resistance in a neonate with venous thrombosis.
Activated protein C resistance in anterior ischaemic optic neuropathy.
Activated protein C resistance in antiphospholipid thrombosis syndrome.
Activated protein C resistance in Behçet's disease.
Activated protein C resistance in Behcet's disease.
Activated Protein C Resistance in Behçet's Disease.
Activated protein C resistance in Budd-Chiari syndrome.
Activated protein C resistance in cases of cerebral infarction.
Activated protein C resistance in central retinal vein occlusion.
Activated protein C resistance in childhood stroke.
Activated protein C resistance in cord blood from healthy and complicated newborns.
Activated protein C resistance in deep venous thrombosis.
Activated protein C resistance in deep-vein thrombosis.
Activated protein C resistance in homozygous sickle cell disease.
Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.
Activated protein C resistance in normal and pre-eclamptic pregnancies.
Activated protein C resistance in normal pregnancy.
Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.
Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies.
Activated protein C resistance in patients with arterial ischemic stroke.
Activated protein C resistance in patients with central retinal vein occlusion.
Activated protein C resistance in patients with peripheral vascular disease.
Activated protein C resistance in pediatric inflammatory bowel disease.
Activated Protein C Resistance in Polycythemia Vera.
Activated protein C resistance in preeclampsia.
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Activated protein C resistance in the Japanese population due to homozygosity for the factor V R2 haplotype.
Activated protein C resistance in Turkish women with severe preeclampsia.
Activated protein C resistance in type I diabetes.
Activated protein C resistance in venous thrombosis.
Activated protein C resistance in young adults with central retinal vein occlusion.
Activated protein C resistance in young African American patients with ischemic stroke.
Activated protein C resistance is a risk factor for central retinal vein occlusion.
Activated protein C resistance is uncommon in sudden death due to pulmonary embolism.
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.
Activated protein C resistance phenotype in patients with antiphospholipid antibodies.
Activated protein C resistance shows an association with pregnancy-induced hypertension.
Activated protein C resistance test using factor VIII-deficient plasma: a new approach to the venous thrombotic risk?
Activated protein C resistance testing for factor V Leiden.
Activated protein C resistance, factor V Leiden and assessment of thrombotic risk.
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults.
Activated protein C resistance, factor V Leiden, and retinal vessel occlusion.
Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
Activated protein C resistance, thrombophilia, and inflammatory bowel disease.
Activated protein C resistance--a major risk factor for thrombosis.
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation.
Activated protein C resistance: a study among 60 thromboembolic patients in the Singapore population.
Activated protein C resistance: automated detection of the factor V Leiden mutation by mismatch hybridization.
Activated protein C resistance: effect of platelet activation, platelet-derived microparticles, and atherogenic lipoproteins.
Activated protein C resistance: from phenotype to genotype and clinical practice.
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Activated protein C resistance: molecular mechanisms.
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
Activated protein C resistance: the commonest hereditary hypercoagulation disorder.
Activated protein C resistance: the influence of ABO-blood group, gender and age.
Activated protein C resistance: the most common risk factor for venous thromboembolism.
Activated protein C resistance: What have we learned now that the dust has settled?
Activated Protein C-Resistance Determination and Vascular Access Thrombosis in Populations with High Prevalence of Factor V Leiden.
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Acute peripheral vertigo: involvement of the hemostatic system.
Acute proptosis in relation to activated protein C resistance: a case report.
Adult transient lupus anticoagulant patients maintain an acquired activated protein C resistance profile.
Advances in laboratory testing for thrombophilia.
Adverse pregnancy outcomes and inherited thrombophilia.
Air travel-associated venous thromboembolism.
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance.
Alteration of haemostasis in non-metastatic gastric cancer.
An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.
An improved algorithm for activated protein C resistance and factor v leiden screening.
An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
An overview of genetic risk factors in thrombophilia.
An update on hypercoagulable disorders.
Antenatal screening for factor V Leiden mutation: a critical appraisal.
Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature.
Anti-Domain I ?2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid.
Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device.
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort.
APC resistance and third-generation oral contraceptives: Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease.
APC resistance in childhood thromboembolism: diagnosis and clinical aspects.
APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.
Applying risk assessment models in orthopaedic surgery: effective risk stratification.
Assay of protein S in systemic lupus erythematosus.
Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance.
Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R.
Association between in vitro fertilization outcomes and inherited thrombophilias: a meta-analysis.
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
Association of increased C-Reactive Protein and hypocomplementemia with risk factors for thrombosis in women who have susceptibility for poor gestational outcome; importance of preconceptional counseling.
Association of periprocedural neurological deficit in carotid stenting with increased anticardiolipin antibodies.
Association of primary antiphospholipid syndrome with inherited activated protein C resistance.
Association of resistance to activated protein with the presence of Leiden and Cambridge Factor V mutations in Mexican patients with primary thrombophilia.
Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population.
Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina.
Atherosclerosis in women with endometriosis.
Basic parameters of thrombophilia in ocular Behçet disease with posterior segment involvement.
Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Benzylthiouracil-induced ANCA-associated Vasculitis: A Case Report and Literature Review.
Biological coagulation findings in third-generation oral contraceptives.
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.
Broadsheet number 53: Activated protein C resistance: diagnosis and clinical management.
Budd-Chiari syndrome and activated protein C resistance.
Budd-Chiari syndrome in the course of Behcet's disease: clinical and laboratory analysis of four cases.
C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis.
Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.
Cancer procoagulant in patients with adenocarcinomas.
Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation.
Case Study of Pediatric Cerebral Sinus Venous Thrombosis Center of a Low Middle-Income Country.
Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants.
Causes of venous thrombosis in fifty Chinese patients.
Central retinal artery occlusion in a patient homozygous for factor V Leiden.
Central retinal vein thrombosis associated with resistance to activated protein C.
Cerebral sinus thrombosis in a young adult with activated protein C resistance and homosysteinaemia.
Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis.
Cerebral venous thrombosis and activated protein C resistance.
Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation.
Cerebrovascular disease risk factors: neuroradiologic findings in patients with activated protein C resistance.
Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease.
Changes in activated protein C resistance during normal pregnancy.
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Clinical and ethnic characteristics of stroke in an Israeli population: a study in a community hospital population.
Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both.
Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus.
Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state.
Clinically symptomatic central venous catheter-related deep venous thrombosis in newborns.
Coagulation abnormalities in adults with cryptogenic stroke and patent foramen ovale.
Coagulation Factor Levels and Underlying Thrombin Generation Patterns in Adult Extracorporeal Membrane Oxygenation Patients.
Coagulation factor V and thrombophilia: background and mechanisms.
Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis.
Coagulation factor V gene 1691G>A polymorphism as an indicator for risk and prognosis of lower extremity deep venous thrombosis in Chinese Han population.
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
Coagulation inhibitors and activated protein C resistance in recurrent pregnancy losses in Indian women.
Coagulation management of a patient with factor V Leiden mutation, lupus anticoagulant, and activated protein C resistance: a case report.
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality.
Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis.
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Coexistence of preeclampsia and inherited thrombophilia in Turkish pregnant women.
Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.
Combined and sequential use of activated protein C resistance and molecular genetic test for the diagnosis of factor V Leiden: a new laboratory approach.
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables.
Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden.
Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis.
Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Congenital and acquired activated protein C resistance.
Congenital thrombophilia associated to obstetric complications.
Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia.
Correlation between the functional assay for activated protein C resistance and factor V Leiden in the neonate.
Cross-comparison of the genome sequences from human, chimpanzee, Neanderthal and a Denisovan hominin identifies novel potentially compensated mutations.
Cutaneous necrosis in pregnancy secondary to activated protein C resistance in hereditary angioedema.
Cutaneous necrosis revealing the coexistence of an antiphospholipid syndrome with acquired protein S deficiency, factor V Leiden and hyperhomocysteinemia.
Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance.
Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.
Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.
Detection of factor V Leiden in Thai patients with venous thrombosis.
Detection of the factor VLeiden mutation. Development of a testing algorithm combining a coagulation assay and molecular diagnosis.
Determinants and associations of homocysteine and prothrombotic risk factors in Kuwaiti patients with cerebrovascular accident.
Determinants of acquired activated protein C resistance and D-dimer in breast cancer.
Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Determination of Factor V Leiden Mutation and R2 Polymorphism in Cis Position.
Determining the crystal structure of fibrinogen.
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Diagnosis and clinical characteristics of inherited activated protein C resistance.
Diagnosis of activated protein C resistance (factor V Leiden)
Diagnosis of activated protein C resistance in retinal vein occlusion.
Diagnosis strategies in activated protein C resistance: is genotyping still necessary?
Diagnostic issues in thrombophilia: a laboratory scientist's view.
Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
Discordance Between Functional Screening and Genetic Confirmatory Diagnostic Tests: A Retrospective Analysis of Activated Protein C Resistance and Factor 5 Leiden Testing Over a 5-Year Period.
Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?
DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation?
Doppler velocimetry and thrombophilic screening at middle trimester of gestation: preliminary data.
Double hazard of thrombophilia and bleeding in leukemia.
Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family.
Double inherited thrombophilias and adverse pregnancy outcomes: fashion or science?
Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis.
Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.
Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature.
Edoxaban improves atrial fibrillation and thromboembolism through regulation of the Wnt-?-induced PI3K/ATK-activated protein C system.
Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Effect of Freezing Plasma at -20°C for 2 Weeks on Prothrombin Time, Activated Partial Thromboplastin Time, Dilute Russell Viper Venom Time, Activated Protein C Resistance, and d-Dimer Levels.
Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen.
Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening.
Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Effect of urinary versus recombinant follicle-stimulating hormone on platelet function and other hemostatic variables in controlled ovarian hyperstimulation.
Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay.
Effects of anticoagulation protein defect in maternal plasma on spontaneous abortion.
Effects of hormone replacement on hemostasis in spontaneous menopause.
Effects of oral contraceptives on hemostasis and thrombosis.
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.
Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women.
Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
Elevated prothrombin and activated protein C resistance in patients with thoracic aortic atheroma.
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program.
Endogenous or exogenous coagulation factor level and the response to activated protein C.
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.
Epidemiology, risk and prognostic factors in mesenteric venous thrombosis.
Estimates of Within-Subject Biological Variation of Protein C, Antithrombin, Protein S Free, Protein S Activity, and Activated Protein C Resistance in Pregnant Women.
Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy.
Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study.
Etiology and portal vein thrombosis in Budd-Chiari syndrome.
Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway.
Evaluation of a new chronometric assay for factor V Leiden-dependent APC resistance.
Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance.
Evaluation of activated protein C resistance in stored plasma.
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Evaluation of plasma activity level of anticoagulant proteins in patients with acute lymphoblastic leukemia in Shafa hospital Ahwaz 2010.
Evaluation of recurrent thrombosis and hypercoagulability.
Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis.
Evaluation of smoking as a risk factor for activated protein C resistance during pregnancy.
Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke.
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Evolving methods for single nucleotide polymorphism detection: Factor V Leiden mutation detection.
Exercise-induced activation of coagulation in subjects with activated protein C resistance.
Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance.
Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.
External quality assessment and the laboratory diagnosis of thrombophilia.
Factor V (His 1299 Arg) in young Turkish patients with cerebral infarct.
Factor V A4070G (His1299Arg) mutation in Turkish pediatric patients with thrombosis.
Factor V Arg306 --> Gly mutation is not associated with activated protein C resistance and is rare in Taiwanese Chinese.
Factor V Cambridge mutation and activated protein C resistance assays.
Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behçet's disease.
Factor V gene mutation is a risk factor for cerebral venous thrombosis.
Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C.
Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage.
Factor V Leiden and activated protein C resistance.
Factor V Leiden and post thromboembolic pulmonary hypertension.
Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia.
Factor V Leiden in Greek thrombophilic patients: relationship with activated protein C resistance test and levels of thrombin-antithrombin complex and prothrombin fragment 1 + 2.
Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.
Factor V Leiden mutation in a case with ischemic stroke: which relationship? A case report.
Factor V Leiden mutation in one family of Chinese origin.
Factor V Leiden mutation is not increased in patients with inflammatory bowel disease.
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Factor V Leiden prevalence in venous thromboembolism patients.
Factor V Leiden thrombophilia.
Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.
Factor V variants, activated protein C resistance and venous thromboembolism.
Factor V1691 G-A, prothrombin 20210 G-A, and methylenetetrahydrofolate reductase 677 C-T variants in Turkish children with cerebral infarct.
Factor XII deficiency is strongly associated with primary recurrent abortions.
False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract.
Familial antithrombin III deficiency in a Malay patient with massive thrombosis.
Familial coagulation-inhibiting and fibrinolytic protein deficiencies in juvenile transient ischaemic attacks.
Familial coexistence of primary antiphospholipid syndrome and factor VLeiden.
Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
Familial thrombophilia: a complex genetic disorder.
Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemia.
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
First-trimester repeated abortion is not associated with activated protein C resistance.
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Frequency of FV 1299 His-Arg (A4070G) in Turkish Cypriots.
Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Functional diagnosis of activated protein C resistance in patients with antiphospholipid antibodies.
Further evidence that activated protein C resistance affects protein C coagulant activity assays.
Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency.
Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke?
Genetic analysis of factor V Leiden in a family with history of thrombosis and venous leg ulcers.
Genetic determinants of hemostasis phenotypes in Spanish families.
Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR.
Genetic risk factors in myocardial infarction at young age.
Haematologic disorders and cerebral venous thrombosis.
Haemocoagulative modifications correlated with pregnancy.
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.
Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17?-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
HELLP syndrome associated with factor V R506Q mutation.
Hematologic risk factors for stroke in Saudi children.
Hemiretinal Artery Occlusion in an 11-Year-Old Child with Dextrocardia.
Hemostasis during normal pregnancy and puerperium.
Hemostatic alterations in patients with acute, unilateral vestibular paresis.
Hemostatic changes in active pulmonary tuberculosis.
Hemostatic dysfunction in paraproteinemias and amyloidosis.
Heparin induced thrombocytopenia in a patient with factor V Leiden following cardiac surgery.
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Herbal Fufang Xian Ling Gu Bao prevents corticosteroid-induced osteonecrosis of the femoral head-A first multicentre, randomised, double-blind, placebo-controlled clinical trial.
Hereditary angioedema associated with heterozygous factor V Leiden mutation in a patient with Purpura fulminans.
Hereditary Thrombophilic Factors in Glaucoma.
Heritable coagulopathies in pregnancy.
Heterogeneity of activated protein C resistance phenotype in subjects with compound heterozygosity for HR2 haplotype and FV Leiden mutation (R506Q) in factor V gene.
High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis.
High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death.
High prevalence of activated protein C resistance in patients with systemic sclerosis.
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.
High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.
High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors.
Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the above-knee femoro-popliteal artery.
Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the common iliac arteries.
Homocysteine levels, haemostatic risk factors and restenosis after carotid thrombendarterectomy.
Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice.
Homozygosity for the HR2 Haplotype: Is It a Risk Factor for Thrombosis?
Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception.
Hormonal influences on hemostasis in women.
Hormone replacement therapy: prothrombotic vs. protective effects.
Hormone therapies and vascular outcomes: who is at risk?
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Hypercoagulability test strategies in the protein C and protein S pathway.
Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever.
Hypercoagulable state and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with beta-thalassemia major in Kuwait.
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Hypercoagulable states in patients with hepatocellular carcinoma.
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects.
Hyperhomocysteinaemia and activated protein C resistance in Behçet's disease.
Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.
Hyperhomocysteinemia and hypercoagulable state in carotid plaque evolution. Novel risk factors or coincidental risk predictors?
Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy.
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Idiopathic intracranial hypertension and anticardiolipin antibodies.
Impact of activated protein C resistance on general vascular surgical patients.
Implementation of a cost-effective unlabeled probe high-resolution melt assay for genotyping of factor v leiden.
Importance of levonorgestrel dose in oral contraceptives for effects on coagulation.
Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.
Incidence of deep venous thrombosis in patients undergoing obesity surgery.
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
Incidental discovery of a dural arteriovenous fistula in a patient with activated protein C resistance.
Increased acquired activated protein C resistance in unselected patients with hematological malignancies.
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.
Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors.
Increased thromboembolic events after lung transplantation.
Increased Thrombophilic Tendency in Pediatric Cystic Fibrosis Patients.
Individual risk assessment of thrombosis in pregnancy.
Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinaemia.
Influence of plasma platelets on activated protein C resistance assay.
Influence of storage conditions on activated protein C resistance assay.
Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome.
Inherited and acquired thrombophilia: pregnancy outcome and treatment.
Inherited prothrombotic states and ischaemic stroke in childhood.
Inherited thrombophilia and fetal loss.
Inherited thrombophilia and pregnancy.
Inherited Thrombophilia due to Factor V Leiden Mutation.
Inherited thrombophilia in unprovoked venous thromboembolism: Is non 'O' blood group an additional culprit in Indian patients?
Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population.
Inherited thrombophilia.
Inherited thrombophilia: an update.
Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of a?2GPI and aPS/PT antibodies.
Instrument effect on the activated protein C resistance plasma assay performed by a commercial kit.
Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated by thrombin in human monocytes and THP-1 cells in vitro and in pregnant subjects in vivo.
Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome.
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Intraindividual consistency of the activated protein C resistance phenotype.
Investigation of inherited thrombophilias in patients with pulmonary embolism.
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Is acquired activated protein C resistance a cardiovascular risk?
Is activated protein C resistance following orthotopic liver transplantation a risk factor for venous thrombosis?
Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion?
Is lipoprotein(a) regulating prostaglandin I2-synthesis stimulating plasma factor?
Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
Ischemic colitis revisited: a prospective study identifying hypercoagulability as a risk factor.
Ischemic optic neuropathy and giant cell arteritis.
Ischemic stroke and activated protein C resistance.
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds.
Isolated cortical vein thrombosis and activated protein C resistance.
Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations.
Issues concerning the laboratory investigation of inherited thrombophilia.
Juvenile temporal arteritis and activated protein C resistance.
Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age.
LABORATORY EVALUATION OF HYPERCOAGULABLE STATES IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION WHO ARE LESS THAN 56 YEARS OF AGE.
Laboratory investigation of thrombophilia: the good, the bad, and the ugly.
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Laboratory Testing for Activated Protein C Resistance (APCR).
Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference.
Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors--correlation with absence of Arg506-Gln mutation of factor V gene.
Lack of association between inherited thrombophilic risk factors and idiopathic sudden sensorineural hearing loss in Italian patients.
Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colombian Patients.
Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process.
Left ventricular intracardiac thrombus in a patient with Behçet disease successfully treated with immunosuppressive agents without anticoagulation: a case report and review of the literature.
Lemierre syndrome variant: Staphylococcus aureus associated with thrombosis of both the right internal jugular vein and the splenic vein after the exploration of a river cave.
Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
Livedoid vasculopathy in a patient with factor V mutation (Leiden).
Livedoid vasculopathy: thrombotic or inflammatory disease?
Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant.
Liver transplantation for acute Budd-Chiari syndrome in identical twin sisters with Factor V leiden mutation.
Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women.
Low birthweight in relation to placental abruption and maternal thrombophilia status.
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals.
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Preeclampsia in women with Inheritable Thrombophilia: the FRUIT-RCT.
Lupus Anticoagulant Interference in Activated Protein C Resistance Testing: In Vitro Phenomenon or In Vivo Pathophysiologic Effect?
Mali acroangiodermatitis in homozygous activated protein C resistance.
Maternal thrombophilias are not associated with early pregnancy loss.
Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance.
Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation.
Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden).
Mechanisms for acquired activated protein C resistance in cancer patients.
Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.
Mechanisms of thrombosis related to hormone therapy.
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Membranous glomerulonephritis in a patient with inherited activated protein C resistance.
Mesenteric arterial thrombosis due to activated protein C resistance (factor V Leiden)
Mesenteric artery occlusion secondary to activated protein C resistance: a life-threatening combination.
Mesenteric vein thrombosis associated with primary cytomegalovirus infection: a case report.
Mesenteric vein thrombosis due to factor V Leiden gene mutation.
Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.
Modified test for activated protein C resistance.
Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
Molecular biology and pathophysiology of APC resistance: current insights and clinical implications.
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Multi-chamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy.
Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program.
Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia.
Multiple medical problems following agent orange exposure.
Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test.
Mutation screening for thrombophilia: two cases with factor V Cambridge without activated protein C resistance.
Mutations and polymorphisms in genes affecting haemostasis components in children with thromboembolic events.
Mutations and Polymorphisms in Genes Affecting Hemostasis Proteins and Homocysteine Metabolism in Children with Arterial Ischemic Stroke.
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors.
Myocardial infarction and normal coronary arteries: the experience of the cardiology department of sfax, Tunisia.
Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance.
Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease.
Natural anticoagulants and the liver.
Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Neonatal purpura fulminans in association with factor V R506Q mutation.
Neurological deficit after cerebral angiography and activated protein C resistance.
New concepts in coagulation.
New findings on venous thrombogenesis.
No association between thrombosis and factor V gene polymorphisms in Chinese Han population.
No correlation between activated protein C resistance and free flap failures in 100 consecutive patients.
Noonan syndrome and moyamoya.
Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance.
Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis.
Obesity and activated protein C resistance.
Obstetric implications of activated protein C resistance and factor V Leiden mutation.
Oral contraceptives and thrombosis.
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.
Parameters predicting complications in flap surgery.
Performance of a novel test to quantify activated protein C resistance in women with a history of pre-eclampsia.
Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance.
Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis.
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Phenotypic correction of activated protein C resistance following orthotopic liver transplantation.
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V.
Phenotyping and genotyping of coagulation factor V Leiden.
Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation.
Phlegmasia cerulea dolens in a teenage boy found to have Factor V Leiden.
Physical activity and hemostatic and inflammatory variables in elderly men.
Physiological anticoagulants and activated protein C resistance in childhood stroke.
Pitfalls of protein C assays in patients with activated protein C resistance.
Placental prothrombin mRNA levels in APC resistance (APCR) women with increased placental fibrin deposition.
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance.
Plasma cell leukemia: a rare condition.
Plasma homocysteine and hematological factors in patients with venous thromboembolic diseases in Kuwait.
Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.
Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency.
Porcine factor V: cDNA cloning, gene mapping, three-dimensional protein modeling of membrane binding sites and comparative anatomy of domains.
Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders.
Postmortem diagnosis of Factor V Leiden from paraffin wax embedded tissue.
Postnatal screening for thrombophilia in women with severe pregnancy complications.
Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation.
Postpartum seizures after epidural analgesia: a patient with a mutation of the factor V Leiden and prothrombin gene.
Practical applications of snake venom toxins in haemostasis.
Prediction of ischemic stroke in young Indians: is thrombophilia profiling a way out?
Predictors of left ventricular thrombus formation in patients with anterior myocardial infarction: role of activated protein C resistance.
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Preeclampsia is associated with a reduced response to activated protein C.
Pregnancy associated coagulopathies in selected community hospitals in Southwest Nigeria.
Prenatal stroke in a neonate heterozygous for factor V Leiden mutation.
Presumed pre- or perinatal arterial ischemic stroke: risk factors and outcomes.
Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis.
Prevalence and outcome of activated protein C resistance in patients after peripheral arterial bypass grafts.
Prevalence and patient profile in activated protein C resistance.
Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy.
Prevalence of activated protein C resistance (Factor V Leiden) in Lagos, Nigeria.
Prevalence of activated protein C resistance among women with recurrent miscarriage.
Prevalence of activated protein C resistance and analysis of clinical profile in thromboembolic patients. A Belgian prospective study.
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Prevalence of activated protein C resistance in the Chinese population.
Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis.
Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk.
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.
Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion.
Prevalence of factor V Leiden in the Chinese population.
Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.
Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease.
Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.
Prevalence of the Factor V E666D Mutation and Its Correlation With Activated Protein C Resistance in the Chinese Population.
Prevalence of the Factor V Leiden Mutation Arg534Gln in Western Region of Saudi Arabia: Functional Alteration and Association Study With Different Populations.
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.
Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506 -->Gln mutation.
Primary Budd-Chiari syndrome in a 3-year-old boy with homozygous factor V Leiden G1691A mutation.
Primary pulmonary artery sarcoma resembling chronic thromboembolic pulmonary disease.
Primary recurrent miscarriages: anti-beta2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test.
Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome.
Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients.
Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial.
Primary thrombophilia in Mexico: a prospective study.
Primary thrombophilia in Mexico: a single tertiary referral hospital experience.
Primary thrombophilia in Saudi Arabia.
Pro CR global: an effective screening test for thrombophilia.
Profile of prothrombotic factors in Indian children with ischemic stroke.
Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance.
Protein C pathway in infants and children.
Protein C system defects in Indian children with thrombosis.
Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.
Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
Protein Z levels and central retinal vein or artery occlusion.
Prothrombotic disorders in children with moyamoya syndrome.
Prothrombotic disorders in infants and children with cerebral thromboembolism.
Prothrombotic factors and the risk of acute onset non-cardioembolic stroke in young Asian Indians.
Prothrombotic Factors Have Significant Association with Arterial and Venous Strokes in Indian Tamilians.
Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
Pseudo-protein S deficiency due to activated protein C resistance.
Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
Public health approach to activated protein C resistance assay.
Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.
Purpura fulminans in a child with combined heterozygous prothrombin G20210A and factor V Leiden mutations.
Quality standards for sample collection in coagulation testing.
Raised factor VIII is associated with coronary thrombotic events.
Reactions to awareness of activated protein C resistance carriership: a descriptive study of 270 women.
Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes.
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Recurrent thrombosis in a patient with pseudohomozygous activated protein C resistance and homozygosity for MTHFR gene polymorphism C677T.
Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings.
Recurrent thrombotic occlusion of a transjugular intrahepatic portosystemic stent-shunt due to activated protein C resistance.
Recurrent venous thrombosis despite correction of activated protein C resistance following orthotopic liver transplantation.
Reduced Protein C Global Assay Levels in Infertile Women with in vitro Fertilization Failure: A Pilot Study.
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Relationship between homocysteine and thrombotic disease.
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Renal vein thrombosis in a newborn with prothrombotic genetic risk factors.
Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia--the need for a prospective multicentre study.
Resistance to activated protein C and Arg 506 Gln factor V mutation are uncommon in eastern Asian populations.
Resistance to activated protein C and ischemic arterial disease in a young man.
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Resistance to activated protein C and low levels of protein S activity in nine thrombophilic families: a correct diagnosis.
Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
Resistance to activated protein C caused by a factor V gene mutation.
Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.
Resistance to activated protein C: a major cause of inherited thrombophilia.
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Resistance to activated protein C: role in venous and arterial thrombosis.
Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.
Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations.
Risk factors and management of patients with upper limb deep vein thrombosis.
Risk factors for thrombophilia in young adults presenting with thrombosis.
Risk factors for thrombosis in nonembolic cerebrovascular disease.
Risk factors in central retinal vein occlusion an activated protein C resistance.
Risk factors in central retinal vein occlusion and activated protein C resistance.
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study.
Risk of Venous Thrombosis in Carriers of a Common Mutation in the Homocysteine Regulatory Enzyme Methylenetetrahydrofolate Reductase.
Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Role of activated protein C resistance in left atrial thrombogenesis in patients with mitral stenosis.
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.
Role of factor VIII on activated protein C resistance ratio in inflammatory diseases.
Role of hyperhomocystinemia in retinal vascular occlusive disease.
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Routine coagulation tests are not useful as a screening tool for the FII G20210A polymorphism.
Screening for a prothrombotic diathesis in patients attending family planning clinics.
Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation.
Screening for activated protein C resistance before oral contraceptive treatment: a pilot study.
Screening for thrombophilia: a laboratory perspective.
Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance.
Second-trimester pregnancy loss is associated with activated C resistance.
Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children.
Severe thrombotic complications associated with activated protein C resistance acquired by orthotopic liver transplantation.
Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event.
Single inherited thrombophilias and adverse pregnancy outcomes.
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
Soluble Endothelial Protein C Receptor and Coagulation Parameters as Prognostic Factors in Non-Small Cell Lung Cancer.
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Spontaneous neonatal renal vein thromboses: Should we treat them all? A report of five cases and a literature review.
Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home-made methods.
Stroke in a neonate heterozygous for factor V Leiden.
Stroke in children: inherited and acquired factors and age-related variations in the presentation of 48 paediatric patients.
Study of the homocysteine status in children with chronic renal failure.
Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
Successful Living-Related Renal Allograft in a Recipient With Factor V Leiden Deficiency: A Case Report.
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Systemic corticosteroids for the outpatient treatment of necrobiosis lipoidica in a diabetic patient.
Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
Testing for heredity hypercoagulability Activated protein C resistance.
Testing for heritable thrombophilia in children at Starship Children's Hospital: An audit of requests between 2004 and 2009.
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
The association between extrinsic activated protein C resistance and venous thromboembolism in women.
The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
The clinical spectrum of acute renal infarction.
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients.
The cytoprotective protein C pathway.
The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature.
The diagnostic dilemma: dual presentations of clinical mucosal bleeding and venous thrombosis associated with the presence of thrombophilia markers and mild reduction in von Willebrand factor.
The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.
The discovery of activated protein C resistance.
The effect of argatroban on activated protein C resistance.
The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
The effect of dabigatran on select specialty coagulation assays.
The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
The effect of pre-eclampsia on the levels of coagulation and fibrinolysis factors in umbilical cord blood of newborns.
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index.
The effects of transport temperature and time on routine and specialized coagulation assays.
The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura.
The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation.
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia.
The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease.
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels.
The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance.
The Hemostatic Changes in Active Pulmonary Tuberculosis.
The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
The influence of factor VIII on measurement of activated protein C resistance.
The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients.
The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.
The phenomenon known as acquired activated protein C resistance.
The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance.
The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.
The Prevalence of Activated Protein C Resistance and F V Leiden in Healthy Population of Edirne, Turkey.
The prevalence of thrombophilia in patients with chronic venous leg ulceration.
The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease.
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
The role of activated protein C resistance in the pathogenesis of venous thrombosis.
The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis.
The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion.
The thrombophilic state in cancer patients.
The use of direct oral anticoagulants in inherited thrombophilia.
Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Thrombin generation assays: accruing clinical relevance.
Thrombin generation in children with sickle cell Anemia is Higher in the presence of platelets? and ?.
Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis.
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Thrombophilia and activated protein C resistance.
Thrombophilia and fetal loss.
Thrombophilia and first arterial ischaemic stroke: a systematic review.
Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis.
Thrombophilia in Cardiac Surgery-Patients with Symptomatic Factor V Leiden.
Thrombophilia in children with cystic fibrosis.
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Thrombophilia investigation in Malaysian women with recurrent pregnancy loss.
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Thrombophilia-associated pregnancy wastage.
Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta.
Thrombophilia: disorders predisposing to venous thromboembolism.
Thrombophilia: some recent advances in understanding.
Thrombophilia: the discovery of activated protein C resistance.
Thrombophilias and pregnancy complications: a case-control study.
Thrombophilias and recurrent pregnancy loss.
Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis.
Thrombophilic disorders and fetal loss: a meta-analysis.
Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease.
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation.
Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion.
Thrombophilic mutations in pre-eclampsia and pregnancy-induced hypertension.
Thrombophilic risk factors in epileptic children treated with valproic Acid.
Thrombophilic risk factors in patients with central retinal vein occlusion.
Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy patients.
Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study.
Thrombosis and Hemostatic Abnormalities in Hematological Malignancies.
Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden.
Thrombosis in multiple myeloma.
Thrombosis in otherwise well children with the factor V Leiden mutation.
Thrombosis involving the major veins with heterozygote factor V Leiden mutation as the only risk factor.
Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors.
Thrombosis: new culprits in an old disorder.
Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.
Thrombotic disease in the myeloproliferative neoplasms.
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis.
Thrombotic risk factors and oral contraception.
Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy.
Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.
Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy.
Two rare confounding polymorphisms proximal to the factor V Leiden mutation.
Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state.
Underlying disorders associated with severe early-onset preeclampsia.
Understanding activated protein C resistance.
Use of a systematic risk analysis method (FMECA) to improve quality in a clinical laboratory procedure.
Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors.
Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants.
Use of snake venom fractions in the coagulation laboratory.
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
Usefulness of factor V Leiden mutation testing in clinical practice.
Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies.
Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells.
Utilization of testing for activated protein C resistance in a reference laboratory.
Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need.
Variable interference of activated protein C resistance in the measurement of protein S activity by commercial assays.
Vascular graft thrombosis secondary to activated protein C resistance: a case report and literature review.
Vascular surgical society of great britain and ireland: prevalence and significance of thrombophilia in patients with intermittent claudication
Venous gangrene of the upper extremity.
Venous sonography for the diagnosis of asymptomatic deep vein thrombosis in patients with cancer undergoing chemotherapy.
Venous thromboembolic disease: risk factors and laboratory investigation.
Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation.
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Venous thrombosis among patients with AIDS.
Venous thrombosis and oral contraceptives: current status.
Venous thrombosis in older people: prevalence of the factor V gene mutation Q506.
Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
Venous thrombosis: prevalence of prothrombotic defects in north Indian population.
Warfarin induced skin necrosis associated with activated protein C resistance.
[A case report of syphilitic uveitis and deafness.]
[A new cause of familial thrombophilia: resistance to the effect of activated protein C]
[A new cause of hereditary thrombophilia: activated protein c resistance]
[A new cause of hereditary venous thrombosis: activated protein C resistance]
[Abnormalities of haemostasis in myocardial infarction with normal coronary artery]
[Acquired and inherited hypercoagulability among patients with cerebral venous thrombosis]
[Activated C protein resistance manifested by cutaneous necrosis after interferon alpha injection: case report]
[Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population]
[Activated protein C resistance (APC resistance)]
[Activated protein C resistance (APCR) in thromboembolic diseases in Cotonou (Benin)]
[Activated protein C resistance and cardiolipin antibodies in leg ulcers]
[Activated protein C resistance and deep venous thrombosis in pregnancy]
[Activated protein C resistance and factor V Leiden: Clinical interest.]
[Activated protein C resistance and mutation of coagulation factor V]
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]
[Activated protein C resistance as a cause of thrombophilia]
[Activated protein C resistance as the cause of recurrent mesenteric venous thrombosis]
[Activated protein C resistance in Behçet disease]
[Activated protein C resistance in factor V disease: how high is the risk of thrombosis?]
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]
[Activated protein C resistance in patients with venous leg ulcer]
[Activated protein C resistance in the Japanese]
[Activated protein C resistance of an acquired nature: the potential role of hormonal treatment and of elevated factor VIII plasma levels]
[Activated protein C resistance syndrome]
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis]
[Activated protein C resistance--a recently discovered hereditary thrombophilia]
[Activated protein C resistance: role in venous and arterial thrombosis]
[Activated protein C resistance]
[Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism]
[Antiphospholipid thrombosis syndrome and acquired activated protein C resistance]
[APC resistance. Resistance against activated Protein C, a frequent cause of congenital thrombosis susceptibility]
[Assessment of risk factors for retinal vein occlusions in patients under 60 years of age]
[Association of tow thrombotic risk factors: factor V Leiden and hyperhomocysteinemia. A case report]
[Benign intracranial hypertension and heterozygosity for factor V Leiden mutation]
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
[Cerebral panthrombophlebitis in a paucisymptomatic patient]
[Clinical analysis of 12 cases with venous thromboembolism during pregnancy and puerperium]
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]
[Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy]
[Comparison of two groups of 22 women homozygous or heterozygous for factor V Leiden mutation]
[Cutaneous manifestations of activated protein C resistance]
[Deep venous thrombosis in pregnant women]
[Definition of thrombophilia]
[Diagnosis of activated protein C resistance by chronometric test and molecular biology]
[Diagnosis of thrombophilia based on coagulation and genetic studies]
[Evaluation of hemostasis in venous thromboembolism pathology]
[Factor V Leiden and activated protein C resistance]
[Factor V Leiden mutation leads to enhanced atherosclerosis in apolipoprotein E deficient mice]
[Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications]
[From the history of thrombosis prevention and treatment]
[G20210A transition in the prothrombin gene and venous thromboembolic disease]
[Genetic diagnosis of hereditary coagulation disorders]
[Genetic risk factors of venous thromboembolism]
[Genetic trombophilia and markers of endotelial activation in patients with preeclampsia]
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
[Hereditary thrombophilia in free microvascular flaps--a case report]
[High factor VIII as a risk factor for venous thrombosis]
[Hypercoagulable state due to acquired protein C resistance, harbinger of colonic neoplasm?]
[Importance of determination of activated protein C resistance (APC) in gynecology and obstetrics]
[Incidence and risk factors for venous thromboembolism]
[Inherited thrombophilia.]
[Initial experience in the diagnosis of thrombophilia due to activated protein C resistance]
[Intravenous recombinant tissue plasminogen activator in an 18-week pregnant woman with embolic stroke]
[Laboratory tests for detection of antiphospholipid antibodies]
[Mechanisms and risk factors of venous thromboembolic disease]
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
[Multiple phlebothrombosis following cesarean section due to heterozygous factor V Leiden mutation detected post partum]
[National evaluation of the diagnosis of activated protein C resistance]
[New causes of inherited thrombophilia]
[One Chinese case of F V Leiden mutation associated with APC resistance]
[Oral contraceptives and activated protein C resistance: a paradigmatic example of genotype and environment interaction in the development of deep venous thrombosis]
[Paraneoplastic superior vena cava thrombosis disclosing an ovarian tumor]
[Pathophysiology and clinical manifestations in pre-eclampsia]
[Pregnancy outcomes in a patient-heterozygous carrier of R506Q mutation of factor V (Leiden)]
[Prevalence of Factor V Leiden and the G20210A mutation of the prothrombin gene in a random group of patients with thrombotic episodes]
[Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis]
[Prevalence of the activated protein C resistance in indigenous and Black populations of the western Venezuela]
[Priapism and activated protein C resistance]
[Primary thrombophilia in México. VI: lack of statistical association among the inherited thrombophilic conditions]
[Pulmonary embolism disclosing activated protein C resistance]
[Pulmonary embolism in a 30 year-old man with chronic hepatitis C during therapy with pegylated interferon-? and ribavirin].
[Recurrent thrombophlebitis and ulcera crurum as manifestations of hereditary blood coagulation disorders and Klinefelter syndrome. Discussion based on 4 case examples]
[Relationship between phenomenon of acquired activated protein C resistance and antiphospholipid antibodies in patients with systemic lupus erythematosus]
[Resistance to activated protein C and pregnancy: thromboprophylaxis with low molecular weight heparin]
[Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations]
[Resistance to activated protein C, so-called APC resistance: the first two cases in Slovakia]
[Role of gene polymorphism in development of thromboses]
[Screening in activated protein C resistance]
[Study of activated protein C resistance(APC-R) and FV Leiden in healthy blood donors and patients with thrombosis]
[Study on activated protein C resistance and disordered coagulation in patients with myeloproliferative neoplasms].
[Study on relationship of activated protein C resistance and recurrent spontaneous abortion]
[The contribution of the hematological examination in patients with retinal vein occlusion]
[The role of protein C in the pathogenesis of stroke]
[The role of resistance to C active protein (R-APC) in a pediatric stroke]
[The routine coagulation tests along with activated protein C resistance (APC-R) in population of women applying for oral contraceptives]
[Thrombophilia factors as inducers of retinal vascular occlusion]
[Thrombophilia in systemic lupus erythematosus: A case-control study].
[Thrombophilias associated with cerebral venous thrombosis]
[Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment]
[Thrombosis of the cerebral venous sinuses: a description of its clinical features, risk factors and treatment in a hospital of Colombia]
[Thrombosis risk in activated protein C resistance deficiency?]
[Type I protein C deficiency caused by a novel protein C gene mutation]
[Venous thromboembolism in connection with physical restraint]
Acute Coronary Syndrome
A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes.
Acute Kidney Injury
Activated protein C ameliorates impaired renal microvascular oxygenation and sodium reabsorption in endotoxemic rats.
Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2.
Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1.
Acute kidney injury: Activated protein C protective in IRI.
Distinct functions of activated protein C differentially attenuate acute kidney injury.
Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice.
Acute Lung Injury
A plethora of angiopoietin-2 effects during clinical sepsis.
Activated Protein C and Normal Saline Infusion Might Prevent Deleterious Effects of Remote Acute Lung Injury Caused by Intestinal Ischemia-Reperfusion: An Experimental Study in the Rat Model.
Activated Protein C Attenuates Acute Lung Injury and Apoptosis in a Hyperoxic Animal Model.
Activated protein C attenuates cardiopulmonary bypass-induced acute lung injury through the regulation of neutrophil activation.
Activated protein C attenuates intestinal reperfusion-induced acute lung injury: an experimental study in a rat model.
Activated protein C attenuates ischemia-reperfusion-induced acute lung injury.
Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome.
Activated protein C inhalation: a novel therapeutic strategy for acute lung injury.
Activated protein C protection from lung inflammation in endotoxin-induced injury.
Can we reduce mortality in sepsis?
Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis.
Direct Effects of Protein S in Ameliorating Acute Lung Injury.
Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.
Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury.
Effects of recombinant human activated protein C in human models of endotoxin administration.
Enhancing autophagy with activated protein C and rapamycin protects against sepsis-induced acute lung injury.
Heme oxygenase-1 modulates thrombomodulin and activated protein c levels to attenuate lung injury in cecal ligation and puncture-induced acute lung injury mice.
Impact of introducing multiple evidence-based clinical practice protocols in a medical intensive care unit: a retrospective cohort study.
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment.
Inhaled activated protein C: a new therapy for the prevention of ventilator-induced lung injury?
On the randomized trial of activated protein C in acute lung injury.
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.
Randomized clinical trial of activated protein C for the treatment of acute lung injury.
Recently published papers: Pseudomonas, brain and bowel injury and novel cardiac therapies.
Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock.
Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis.
Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?
Recombinant human activated protein C in experimental models of acute lung injury: the timing is critical!
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury.
Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
[Protocol of the management of patients with severe sepsis and septic shock].
Acute Radiation Syndrome
Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin.
Adenocarcinoma of Lung
Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma.
Adrenal Insufficiency
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Alzheimer Disease
Activated protein C: therapeutic implications for Alzheimer's disease.
Increased Levels of Coagulation Factor XI in Plasma Are Related to Alzheimer's Disease Diagnosis.
Anaphylaxis
Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.
Anemia
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
New concepts in sepsis.
Anemia, Hemolytic, Autoimmune
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Anemia, Iron-Deficiency
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Anemia, Sickle Cell
Activated protein C resistance in homozygous sickle cell disease.
Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Angioedemas, Hereditary
Cutaneous necrosis in pregnancy secondary to activated protein C resistance in hereditary angioedema.
Antiphospholipid Syndrome
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.
Anti-Domain I ?2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Association of primary antiphospholipid syndrome with inherited activated protein C resistance.
Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay.
Double hazard of thrombophilia and bleeding in leukemia.
Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome.
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.
Myocardial infarction and normal coronary arteries: the experience of the cardiology department of sfax, Tunisia.
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506 -->Gln mutation.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases.
The inhibition of protein C anticoagulant activity by anti-?2-glycoprotein I (?2GPI) antibodies isolated from patients with antiphospholipid syndrome by chromatography methods.
[Hereditary thrombophilia in free microvascular flaps--a case report]
[Prothrombotic states and cerebral ischemia]
Antithrombin III Deficiency
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
Heritable coagulopathies in pregnancy.
Inherited thrombophilia and pregnancy.
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Risk factors for thrombophilia in young adults presenting with thrombosis.
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage.
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Underlying disorders associated with severe early-onset preeclampsia.
[A childhood case of antiphospholipid syndrome]
[Thrombosis of the cerebral venous sinuses: a description of its clinical features, risk factors and treatment in a hospital of Colombia]
Arrhythmias, Cardiac
Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
Arterial Occlusive Diseases
Diminished response to activated protein C is not correlated with severity of peripheral arterial occlusive disease.
Arteriosclerosis
The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Arthritis
Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice.
Multiple medical problems following agent orange exposure.
Arthritis, Rheumatoid
Activated protein C targets immune cells and rheumatoid synovial fibroblasts to prevent inflammatory arthritis in mice.
Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis.
Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2.
Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes.
From coagulation to inflammation: novel avenues for treating rheumatoid arthritis with activated protein C.
Increased levels of serum histone H4 and activated protein C in patients with active rheumatoid arthritis.
Asthma
Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial.
Activated protein C modulates the proinflammatory activity of dendritic cells.
Inhalational use of antithrombotics in humans: Review of the literature.
Atherosclerosis
Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes.
Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys.
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system.
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease.
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
[Factor V Leiden mutation leads to enhanced atherosclerosis in apolipoprotein E deficient mice]
Atrial Fibrillation
Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report.
The clinical spectrum of acute renal infarction.
Autoimmune Diseases
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease.
Avitaminosis
Laboratory diagnosis of thrombophilic states: where do we stand?
Laboratory investigation of thrombophilia.
Bacterial Infections
Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice.
Behcet Syndrome
Activated protein C resistance in Behcet's disease.
[Activated protein C resistance in Behçet disease]
Blood Coagulation Disorders
[A newly discovered blood coagulation disorder. Resistance to activated protein C as a cause of thrombosis]
Brain Edema
Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis.
Brain Infarction
Functional recovery after embolic stroke in rodents by activated protein C.
Brain Injuries
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Effects of activated protein C on neonatal hypoxic ischemic brain injury.
Evaluation of 3K3A-Activated Protein C to Treat Neonatal Hypoxic Ischemic Brain Injury in the Spiny Mouse.
Neonatal brain injury and systemic inflammation: modulation by activated protein C ex vivo.
Brain Injuries, Traumatic
[Intensive care medicine -- update 2004]
Brain Ischemia
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats.
Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia.
Breast Neoplasms
Acquired resistance to activated protein C in breast cancer patients.
Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction.
Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.
An innovative immunosensor for ultrasensitive detection of breast cancer specific carbohydrate (CA 15-3) in unprocessed human plasma and MCF-7 breast cancer cell lysates using gold nanospear electrochemically assembled onto thiolated graphene quantum dots.
Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device.
Determinants of acquired activated protein C resistance and D-dimer in breast cancer.
Functional impairment of activated protein C in breast cancer - relationship to survival outcomes.
Immunosensing of breast cancer tumor protein CA 15-3 (carbohydrate antigen 15.3) using a novel nano-bioink: A new platform for screening of proteins in human biofluids by pen-on-paper technology.
Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients.
Ultrasensitive immunoassay of tumor protein CA 15.3 in MCF-7 breast cancer cell lysates and unprocessed human plasma using gold nanoparticles doped on the structure of mesoporous silica.
Budd-Chiari Syndrome
Activated protein C resistance in Budd-Chiari syndrome.
Acute Budd-Chiari syndrome treated by liver transplantation in a woman homozygous for factor V Leiden.
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Budd-Chiari syndrome and activated protein C resistance.
Budd-Chiari syndrome during nephrotic relapse in a patient with resistance to activated protein C clotting inhibitor.
Liver transplantation in a patient with Budd-Chiari syndrome secondary to factor V Leiden mutation.
Carcinoma
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.
Carcinoma, Hepatocellular
Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin.
Cardiac Papillary Fibroelastoma
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Cardiomyopathies
[Sepsis and heart]
Cardiomyopathy, Dilated
Multi-chamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy.
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Cardiovascular Diseases
Membranous glomerulonephritis in a patient with inherited activated protein C resistance.
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
Carotid Artery Diseases
Inverse correlation between activated protein C generation and carotid atherosclerosis in Type 2 diabetic patients.
Carpal Tunnel Syndrome
Multiple medical problems following agent orange exposure.
Cavernous Sinus Thrombosis
Acute proptosis in relation to activated protein C resistance: a case report.
Central Nervous System Vascular Malformations
Association of resistance to activated protein C and dural arteriovenous fistulas.
Incidental discovery of a dural arteriovenous fistula in a patient with activated protein C resistance.
Cerebral Infarction
Activated protein C resistance in cases of cerebral infarction.
The factor V Leiden mutation (R506Q) is not a major risk factor for migrainous cerebral infarction.
[Prothrombotic states and cerebral ischemia]
Cerebral Palsy
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Cerebrovascular Disorders
Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
Cerebrovascular disease risk factors: neuroradiologic findings in patients with activated protein C resistance.
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.
Response to activated protein C and cerebrovascular disease.
Chagas Disease
Human acute Chagas disease: changes in factor VII, activated protein C and hepatic enzymes from patients of oral outbreaks in Pará State (Brazilian Amazon).
Choroidal Neovascularization
Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction.
Chronic Limb-Threatening Ischemia
APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.
coagulation factor xiia deficiency
Pathogenetic potential of antiphospholipid antibodies.
Coinfection
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Colitis, Ischemic
Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
Ischemic colitis, pulmonary embolism, and right atrial thrombosis in a patient with inherited resistance to activated protein C.
Colitis, Ulcerative
Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis.
Colorectal Neoplasms
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.
Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Communicable Diseases
Anti-apoptotic effect of activated protein C on lipopolysaccharide-stimulated human umbilical vein endothelial cells is associated with the inhibition of the caspase-3 pathway.
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Confusion
[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]
Congenital Abnormalities
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Protein C pathway in infants and children.
Resistance to activated protein C due to a factor V gene mutation The most common inherited risk factor of thrombosis.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Venous thrombosis and procoagulant factors in high-risk neuroblastoma.
Coronary Artery Disease
Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population.
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease.
No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.
Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
[Protocol of the management of patients with severe sepsis and septic shock].
Coronary Disease
Activated protein C ratio, plasma tissue factor activity and activated factor VII in Chinese patients with coronary heart disease.
Activated protein C resistance and Japanese NIDDM patients with coronary heart disease.
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
Coronary Thrombosis
Early identification of acute myocardial infarction by activated protein C--protein C inhibitor complex.
Cough
Adjunctive therapies for community-acquired pneumonia: a systematic review.
COVID-19
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.
Craniocerebral Trauma
Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
Controversial treatment of a victim of severe head injury complicated by septic shock and acute respiratory distress syndrome.
Crohn Disease
An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease.
Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease.
Cytomegalovirus Infections
The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis.
Death, Sudden, Cardiac
Decreased activated protein C levels as a clinical predictor in patients with ST-elevation myocardial infarction.
Deficiency Diseases
Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.
Dehydration
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Dementia
Response to activated protein C in subjects with and without dementia. The Dutch Vascular Factors in Dementia Study.
Dengue
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
Diabetes Complications
Factor V Leiden mutation and type 1 diabetes mellitus.
Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.
Diabetes Mellitus
Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes.
Multiple medical problems following agent orange exposure.
Diabetes Mellitus, Type 1
Enhanced anticoagulant response to activated protein C in patients with IDDM.
Factor V Leiden mutation and type 1 diabetes mellitus.
Lupus anticoagulant positivity in insulin dependent diabetic patients: an additional risk factor in the pathogenesis of diabetic retinopathy?
Diabetes Mellitus, Type 2
A family history of type 2 diabetes is associated with lower sensitivity to activated protein C in overweight and obese premenopausal women.
Activated protein C resistance and Japanese NIDDM patients with coronary heart disease.
Decreased activated protein C levels are inversely associated with the urinary albumin excretion rate in patients with type 2 diabetes.
Diabetic Nephropathies
Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.
Activated protein C and diabetic nephropathy.
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.
Decreased activated protein C levels are inversely associated with the urinary albumin excretion rate in patients with type 2 diabetes.
Exogenous activated protein C inhibits the progression of diabetic nephropathy.
Podocyte Integrin-?3 and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy.
Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice.
Signal integration at the PI3K-p85-XBP1 hub endows coagulation protease activated protein C with insulin-like function.
Diabetic Neuropathies
Multiple medical problems following agent orange exposure.
Disseminated Intravascular Coagulation
A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation.
Activated protein C does not increase in the early phase of trauma with disseminated intravascular coagulation: comparison with acute coagulopathy of trauma-shock.
Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption.
Advances in sepsis therapy.
Assessment of the Interplay between Blood and Skin Vascular Abnormalities in Adult Purpura Fulminans.
Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin.
Comparison of hemorrhagic effect of heparin and human activated protein C with use of Thrombostat 4000.
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Effect of activated protein C on impaired fibrinolysis in rats with obstructive jaundice.
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Plasma soluble fibrin monomer complex is a useful predictor of disseminated intravascular coagulation in neonatal sepsis.
Pregnancy associated coagulopathies in selected community hospitals in Southwest Nigeria.
Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation.
Study of protein C, protein S, and antithrombin III in newborns with sepsis.
The effect of activated protein C in the experimental disseminated intravascular coagulation model formed by lipopolysaccharide infusion.
The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients.
Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients.
Treatment of patients with disseminated intravascular coagulation by protein C.
[Blood plasma resistance to activated protein C as a risk factor of disseminated intravascular coagulation in acute-poisoned patients]
[Diagnosis and correction of thrombohemorrhagic complications in cardiosurgical patients in the early postoperative period].
Eclampsia
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Eisenmenger Complex
Dual endothelin-1 receptor antagonism attenuates platelet-mediated derangements of blood coagulation in Eisenmenger syndrome.
Embolic Stroke
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Functional recovery after embolic stroke in rodents by activated protein C.
Embolism
A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C.
Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation?
Incidence of deep venous thrombosis in patients undergoing obesity surgery.
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors.
Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin.
Resistance to activated protein C and digital thrombosis.
Encephalomyelitis
Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation.
Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells.
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation.
Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells.
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Endocarditis
Safety evaluation of Lactobacillus delbrueckii subsp. lactis UO 004, a probiotic bacterium.
Endotoxemia
Activated protein C ameliorates impaired renal microvascular oxygenation and sodium reabsorption in endotoxemic rats.
Activated protein C improves pial microcirculation in experimental endotoxemia in rats.
Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model.
Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia.
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.
Age-dependent vulnerability to endotoxemia is associated with reduction of anti-coagulant factors activated protein C and thrombomodulin.
Cardiovascular protective role for activated protein C during endotoxemia in rats.
Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studying the role of PCI in physiological and pathological conditions.
Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia: [Effets de la proteine C activee sur la microcirculation mesenterique et la liberation de cytokines durant une endotoxemie experimentale].
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.
Human models of endotoxemia and recombinant human activated protein C.
Increased coagulation and suppressed generation of activated protein C in aged mice during intra-abdominal sepsis.
Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep.
Recombinant human activated protein C improves endotoxemia-induced endothelial dysfunction: A blood free model in isolated mouse arteries.
Release and activity of histone in diseases.
Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.
The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia.
The effect of inflammation on coagulation and vice versa.
The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia.
The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b.
Enterocolitis, Necrotizing
Activated protein C reduces intestinal injury in an experimental model of necrotizing enterocolitis.
Resistance to activated protein C in newborns with necrotizing enterocolitis.
Erythema Infectiosum
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Escherichia coli Infections
Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents.
Exophthalmos
Acute proptosis in relation to activated protein C resistance: a case report.
Fabry Disease
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance.
Factor V Deficiency
Association of severe haemophilia A and factor V Leiden: report of three cases.
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia.
Factor XII Deficiency
Pathogenetic potential of antiphospholipid antibodies.
Fasciitis, Necrotizing
[Monitoring of plasma disappearance rate of indocyanine green in a patient with necrotizing fasciitis and septic shock]
Fatty Liver
Complications of acute fatty liver of pregnancy treated with activated protein C.
Fetal Death
Activated protein C resistance and adverse pregnancy outcome.
High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death.
Fetal Growth Retardation
Activated protein C prevents development of phosphatidylserine-induced intrauterine growth restriction in mice.
Activated protein C resistance and adverse pregnancy outcome.
Foramen Ovale, Patent
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Gastritis
Role of activated protein C in Helicobacter pylori-associated gastritis.
Gastrointestinal Neoplasms
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Genetic Diseases, Inborn
Activated protein C resistance and adverse pregnancy outcome.
Factor V Leiden thrombophilia.
Familial thrombophilia: clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency.
Giant Cell Arteritis
Juvenile temporal arteritis and activated protein C resistance.
Glaucoma
[Assessment of risk factors for retinal vein occlusions in patients under 60 years of age]
Glomerulonephritis
[Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis]
Glomerulonephritis, Membranous
Association of membranous nephropathy with familial resistance to activated protein C.
Membranous glomerulonephritis in a patient with inherited activated protein C resistance.
Graft vs Host Disease
Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells.
Hearing Loss, Noise-Induced
Activated protein C rescues the cochlea from noise-induced hearing loss.
Heart Arrest
Effects of activated protein C on post cardiac arrest microcirculation: an in vivo microscopy study.
Heart Defects, Congenital
Low arterial saturation is associated with increased sensitivity to activated protein C in children with congenital heart disease.
Heart Diseases
Intracardiac thrombus associated with resistance to activated protein C.
Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Heart Failure
The Cardioprotective Signaling Activity of Activated Protein C in Heart Failure and Ischemic Heart Diseases.
[Can we afford the costs of progress in intensive care medicine? A plea for a candid debate]
HELLP Syndrome
HELLP syndrome and factor V Leiden.
HELLP syndrome associated with factor V R506Q mutation.
Hematologic Diseases
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Hematologic Neoplasms
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Increased acquired activated protein C resistance in unselected patients with hematological malignancies.
Hemochromatosis
Multiple medical problems following agent orange exposure.
Hemoglobinopathies
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Hemophilia A
Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.
Emerging applications of aptamers for anticoagulation and hemostasis.
Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.
Moderation of hemophilia A phenotype by the factor V R506Q mutation.
Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab.
Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.
Mutations of factor VIII cleavage sites in hemophilia A.
Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.
Targeting activated protein C to treat hemophilia.
The plasma concentration of activated protein C appears normal in patients with haemophilia.
Hemorrhagic Fever, Ebola
Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever.
Hemostatic Disorders
Laboratory Testing for Activated Protein C Resistance (APCR).
Hepatitis
Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation.
HIV Infections
Defects in assembly explain reduced antiviral activity of the G249D polymorphism in human TRIM5?.
Homocystinuria
Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.
Hydrocephalus
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Resistance to activated protein C (APC) in childhood hydrocephalus.
Hyperalgesia
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity.
Hypercholesterolemia
Activated protein C resistance is a risk factor for central retinal vein occlusion.
Hyperglycemia
Evidence-based management of critically ill patients: analysis and implementation.
Impact of introducing multiple evidence-based clinical practice protocols in a medical intensive care unit: a retrospective cohort study.
Molecular mechanisms of diabetic vascular complications.
[New therapeutic strategies in severe sepsis and septic shock]
Hyperhomocysteinemia
An update on hypercoagulable disorders.
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Cerebral venous thrombosis and procoagulant factors--a case study.
Clinical and ethnic characteristics of stroke in an Israeli population: a study in a community hospital population.
Congenital thrombophilia associated to obstetric complications.
Cutaneous necrosis revealing the coexistence of an antiphospholipid syndrome with acquired protein S deficiency, factor V Leiden and hyperhomocysteinemia.
Diagnostic algorithm for thrombophilia screening.
Effect of hyperhomocysteinemia on protein C activation and activity.
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.
Homocysteine and human reproduction.
Inherited and acquired thrombophilia: pregnancy outcome and treatment.
Inherited thrombophilia and pregnancy: the obstetric perspective.
Inherited thrombophilia: an update.
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Laboratory diagnosis of thrombophilic states: where do we stand?
Laboratory investigation of thrombophilia.
Maternal thrombophilias are not associated with early pregnancy loss.
Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why.
Perinatal aspects of inherited thrombophilia.
Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis.
Relationship between homocysteine and thrombotic disease.
Risk factors for venous thrombosis: prevalence, risk, and interaction.
Thrombophilia and fetal loss.
Thrombophilia-associated pregnancy wastage.
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Thrombosis: new culprits in an old disorder.
Underlying disorders associated with severe early-onset preeclampsia.
Update on selected inherited venous thrombotic disorders.
[A case report of syphilitic uveitis and deafness.]
[Definition of thrombophilia]
[Genetic risk factors of venous thromboembolism]
[Inherited thrombophilia.]
[Risk factors of venous thromboembolism]
Hyperlipidemias
Coagulopathies and osteonecrosis.
[Epidemiological risk factors for non-traumatic osteonecrosis]
Hypersensitivity
Activated protein C modulates the proinflammatory activity of dendritic cells.
Coagulopathies and osteonecrosis.
[Epidemiological risk factors for non-traumatic osteonecrosis]
Hypertension
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.
Hypertension, Pregnancy-Induced
Activated protein C resistance shows an association with pregnancy-induced hypertension.
Hyperventilation
Recently published papers: Pseudomonas, brain and bowel injury and novel cardiac therapies.
Hypotension
Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide.
Activated protein C suppresses adrenomedullin and ameliorates lipopolysaccharide-induced hypotension.
High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats.
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside.
[Treatment of severe sepsis and septic shock]
Idiopathic Pulmonary Fibrosis
[Protein C system in patients with idiopathic pulmonary fibrosis - preliminary report.]
Infections
Activated protein C for H1N1 influenza? More work to do!
Anti-inflammatory effect of activated protein C in gastric epithelial cells.
Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis.
Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients.
Double hazard of thrombophilia and bleeding in leukemia.
Drotrecogin alfa.
Effect of recombinant human activated protein C on the bactericidal activity of human monocytes and modulation of pro-inflammatory cytokines in the presence of antimicrobial agents.
Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Future perspectives on regulating pro-and anti-inflammatory responses in sepsis.
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment.
New concepts in sepsis.
Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.
Pneumonia, thrombosis and vascular disease.
Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report.
Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
Sepsis strategies in development.
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease.
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
Voltage-Dependent Anion Channel Protein 2 (VDAC2) and Receptor of Activated Protein C Kinase 1 (RACK1) Act as Functional Receptors for Lymphocystis Disease Virus Infection.
[Can we afford the costs of progress in intensive care medicine? A plea for a candid debate]
[New therapy strategies for treatment of severe sepsis and septic shock in intensive care unit of clinical centre in Kragujevac]
[Novel treatment for severe sepsis: recombinant human protein C (RHAPC)]
Inflammatory Bowel Diseases
Activated protein C resistance in pediatric inflammatory bowel disease.
Activated protein C resistance, thrombophilia, and inflammatory bowel disease.
Effects of dermatan sulfate derivatives on platelet surface P-selectin expression and protein C activity in blood of inflammatory bowel disease patients.
Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
Influenza, Human
Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Nebulized activated protein C in a paediatric patient with severe acute respiratory distress syndrome secondary to H1N1 influenza.
Intracranial Aneurysm
Incidental discovery of a dural arteriovenous fistula in a patient with activated protein C resistance.
Intracranial Hemorrhage, Traumatic
Successful treatment of severe sepsis with recombinant human activated protein C in a patient with traumatic intracranial hemorrhage.
Intracranial Hemorrhages
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis.
Study of protein C, protein S, and antithrombin III in newborns with sepsis.
Iron Deficiencies
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Ischemic Attack, Transient
Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies.
Resistance to activated protein C in adults with a history of juvenile transient ischemic attacks.
Ischemic Stroke
?-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-? in stroke.
A hypercoagulable state in activated protein C resistant patients with ischemic stroke.
Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.
Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
Activated protein C and ischemic stroke.
Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation.
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Activated protein C resistance due to a factor V mutation associated with familial ischemic stroke.
Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.
Activated protein C resistance in patients with arterial ischemic stroke.
Activated protein C resistance in young African American patients with ischemic stroke.
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.
Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.
Cytoprotective-selective activated protein C therapy for ischaemic stroke.
Diagnostic testing for coagulopathies in patients with ischemic stroke.
Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study.
Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke.
FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke.
Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of tPA and of tPA on the variant's anticoagulant activity.
Ischemic stroke and activated protein C resistance.
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C.
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds.
Low prevalence of the factor V Leiden among patients with ischemic stroke.
Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.
NF-?B-dependent and -independent pathways in the protective effects of activated protein C in hippocampal and cortical neurons at excitotoxicity.
NON-activated protein C as post-treatment after spinal cord compression injury in rats.
Physiological cerebrovascular remodeling in response to chronic mild hypoxia: A role for activated protein C.
Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke.
Prevalence of high IgM anticardiolipins in patients with ischemic stroke.
Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies.
Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.
Prothrombotic Factors Have Significant Association with Arterial and Venous Strokes in Indian Tamilians.
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model.
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy.
[Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment]
Kidney Failure, Chronic
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis.
Safety and dose-finding study of activated protein C (drotrecogin alfa activated) as an anticoagulant in end-stage renal disease patients treated with hemodialysis.
Leg Ulcer
A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers.
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Resistance to activated protein C in patients with venous leg ulcers.
Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial.
Treatment of chronic leg ulcers with topical activated protein C.
[Activated protein C resistance and cardiolipin antibodies in leg ulcers]
[Activated protein C resistance in patients with venous leg ulcer]
Legg-Calve-Perthes Disease
Absence of congenital prethrombotic disorders in children with Legg-Perthes disease.
Resistance to activated protein C and Legg-Perthes disease.
The role of inherited thrombotic disorders in the etiology of Legg-Calvé-Perthes disease.
The role of protein C, protein S, and resistance to activated protein C in Legg-Perthes disease.
Leptospirosis
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Leukemia
Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner.
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.
Leukemia, Hairy Cell
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activated Protein C Resistance in Polycythemia Vera.
Leukopenia
Neuroprotection by recombinant thrombomodulin.
Liver Cirrhosis
Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.
Liver Diseases
Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats.
Increased bleeding risk associated with the use of recombinant human activated protein C in patients with advanced liver disease.
Liver Failure, Acute
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Lung Diseases
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Lung Injury
Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.
Activated protein C attenuates acid-aspiration lung injury in rats.
Activated protein C attenuates leukocyte elastase-induced lung injury in mice.
Activated protein C inhibits lung injury induced by LPS via downregulating MAPK signaling.
Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases.
Cytoprotective-selective Activated Protein C Attenuates P. aeruginosa-induced Lung Injury in Mice.
Heme oxygenase-1 modulates thrombomodulin and activated protein c levels to attenuate lung injury in cecal ligation and puncture-induced acute lung injury mice.
Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice.
Inhaled aerosolized recombinant human activated protein C ameliorates endotoxin-induced lung injury in anesthetized sheep.
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations.
Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models.
Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep.
Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep.
Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury.
Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response.
Lung Neoplasms
Multiple medical problems following agent orange exposure.
The functional properties of a truncated form of endothelial cell protein C receptor generated by alternative splicing.
Lupus Erythematosus, Systemic
Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus.
Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.
Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus.
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus.
Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II.
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Resistance to activated protein C in systemic lupus erythematosus patients with antiphospholipid antibodies.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
[Relationship between phenomenon of acquired activated protein C resistance and antiphospholipid antibodies in patients with systemic lupus erythematosus]
Lupus Nephritis
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Lymphedema
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Lymphohistiocytosis, Hemophagocytic
Differences between adult and pediatric septic shock.
Lymphoma
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Macular Edema
Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results.
Malaria
Activated protein C in neuroprotection and malaria.
Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis.
Severe adult malaria is associated with specific PfEMP1 adhesion types and high parasite biomass.
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
The use of activated protein C in severe Plasmodium falciparum malaria.
[Activated protein C (Xigris) during severe imported malaria: look at benefit/risk ratio]
[Activated protein C in severe plasmodium falciparum malaria.]
[Is there a place for activated protein C (Xigris) in the treatment of severe imported malaria in the adult?]
Malaria, Falciparum
The use of activated protein C in severe Plasmodium falciparum malaria.
[Activated protein C in severe plasmodium falciparum malaria.]
Melanoma
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation.
Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes.
Melioidosis
Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)*
Recent development in melioidosis.
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
Meningitis, Bacterial
Subarachnoid haemorrhage following activated protein C for bacterial meningitis.
Mesenteric Ischemia
Activated protein C resistance associated with lupus anticoagulants is a high risk in acute mesenteric venous thrombosis.
[Activated protein C resistance as the cause of recurrent mesenteric venous thrombosis]
[Upper mesenteric venous thrombosis revealing familial resistance to activated protein C]
Mitral Valve Stenosis
Role of activated protein C resistance in left atrial thrombogenesis in patients with mitral stenosis.
Monoclonal Gammopathy of Undetermined Significance
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Multiple Myeloma
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Pulmonary embolism as the first manifestation of multiple myeloma.
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Multiple Sclerosis
Activated protein C: possible therapeutic implications for multiple sclerosis.
The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
Myocardial Infarction
A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes.
Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
Activated protein C resistance and myocardial infarction.
Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction.
Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions.
Decreased activated protein C levels as a clinical predictor in patients with ST-elevation myocardial infarction.
Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: comparison with unfractionated heparin.
Endothelial protein C receptor polymorphisms and risk of myocardial infarction.
Evaluation of activated protein C on canine infarct size in a nonthrombotic model of myocardial reperfusion injury.
Evidence against heterozygous coagulation factor V 1691 G-->A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction.
Myocardial infarction associated with homozygous resistance to activated protein C.
Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C.
Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance.
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Predictors of left ventricular thrombus formation in patients with anterior myocardial infarction: role of activated protein C resistance.
Prevalence of activated protein C resistance in acute myocardial infarction in Japan.
Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction.
Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.
Resistance to activated protein C and risk of premature myocardial infarction.
Resistance to activated protein C: role in venous and arterial thrombosis.
Risk of myocardial infarction related to factor V Leiden mutation: a meta-analysis.
[Activated protein C resistance: role in venous and arterial thrombosis]
[Evaluation of resistance to activated protein C in myocardial infarction patients]
[Resistance to activated protein C in a patient with multiple myocardial infarctions and stroke--a case report]
Myocardial Ischemia
The Cardioprotective Signaling Activity of Activated Protein C in Heart Failure and Ischemic Heart Diseases.
Myocardial Reperfusion Injury
Evaluation of activated protein C on canine infarct size in a nonthrombotic model of myocardial reperfusion injury.
Myocarditis
Successful use of extracorporeal membrane oxygenation and drotrecogin alpha in patients with acute life-threatening myocarditis.
Necrobiosis Lipoidica
Systemic corticosteroids for the outpatient treatment of necrobiosis lipoidica in a diabetic patient.
Neonatal Sepsis
Study of protein C, protein S, and antithrombin III in newborns with sepsis.
Neoplasm Metastasis
Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.
Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma.
Role of activated protein C and its receptor in inhibition of tumor metastasis.
The protein C pathway in cancer metastasis.
Neoplasms
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Acquired activated protein C resistance in sarcoma patients.
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Activated protein C attenuates cardiopulmonary bypass-induced acute lung injury through the regulation of neutrophil activation.
Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation.
Activated protein C improves ischemic flap survival and modulates proangiogenic and antiinflammatory gene expression.
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.
Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes.
Activated Protein C Inhibits Proliferation and Tumour Necrosis Factor ?-stimulated Activation of p38, JNK and Akt in Rheumatoid Synovial Fibroblasts.
Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes.
Activated protein C levels in patients with gynecologic tumors.
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.
An innovative immunosensor for ultrasensitive detection of breast cancer specific carbohydrate (CA 15-3) in unprocessed human plasma and MCF-7 breast cancer cell lysates using gold nanospear electrochemically assembled onto thiolated graphene quantum dots.
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.
Coagulopathies and osteonecrosis.
Complement activation and plasma levels of C4b-binding protein in critical limb ischemia patients.
Determination of coagulation inhibitor levels and resistance to activated protein C in patients undergoing gastric surgery for benign and malignant disorders.
Development and biological evaluation of ??mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers.
Drotrecogin alfa (activated) does not affect intracellular production of interleukin-6 and tumor necrosis factor-alpha in endotoxin-stimulated human monocytes.
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients-a pilot study.
Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-?B inactivation.
Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation.
Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement.
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
EPCR promotes MGC803 human gastric cancer cell tumor angiogenesis in vitro through activating ERK1/2 and AKT in a PAR1-dependent manner.
Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis.
Heme oxygenase 1 modulates thrombomodulin and endothelial protein C receptor levels to attenuate septic kidney injury.
Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C.
Immunosensing of breast cancer tumor protein CA 15-3 (carbohydrate antigen 15.3) using a novel nano-bioink: A new platform for screening of proteins in human biofluids by pen-on-paper technology.
Impact of chemotherapy on activated protein C-dependent thrombin generation-Association with VTE occurrence.
Inactivation of factor Va by activated protein C on selected human tumor cell lines.
Increased acquired activated protein C resistance in unselected patients with hematological malignancies.
Increased D-dimer levels correlate with binding of activated protein C, but not tissue factor expression, on peripheral blood monocytes in cancer patients.
Inflammatory mediators are associated with 1-year mortality in critical limb ischemia.
Mechanisms for acquired activated protein C resistance in cancer patients.
New findings on venous thrombogenesis.
Paper based immunosensing of ovarian cancer tumor protein CA 125 using novel nano-ink: A new platform for efficient diagnosis of cancer and biomedical analysis using microfluidic paper-based analytical devices (?PAD).
Patterns of markers of inflammation, coagulation and vasoconstriction during folllow-up of abdominal aortic aneurysms.
PO-14 - Tumour expression of coagulation proteases of the aPC pathway - a role in the pathogenesis of gynaecological cancers?
Primary pulmonary artery sarcoma resembling chronic thromboembolic pulmonary disease.
Production and control of coagulation proteins for factor X activation in human endothelial cells and fibroblasts.
Prospective evaluation of patients hospitalized with venous thromboembolism: comparison between cancer and non-cancer patients.
RACK1 is indispensable for porcine reproductive and respiratory syndrome virus replication and NF-?B activation in Marc-145 cells.
Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1.
Risk factors for venous thrombosis: prevalence, risk, and interaction.
Role of activated protein C and its receptor in inhibition of tumor metastasis.
Role of activated protein C in facilitating basement membrane invasion by tumor cells.
Structure of the carbonic anhydrase VI (CA6) gene: evidence for two distinct groups within the alpha-CA gene family.
The protein C pathway in cancer metastasis.
The role of activated protein C in cancer progression.
Thrombophilia and risk of venous thrombosis in patients with cancer.
Ultrasensitive immunoassay of tumor protein CA 15.3 in MCF-7 breast cancer cell lysates and unprocessed human plasma using gold nanoparticles doped on the structure of mesoporous silica.
[Epidemiological risk factors for non-traumatic osteonecrosis]
[Mechanisms and risk factors of venous thromboembolic disease]
[Study on activated protein C resistance and disordered coagulation in patients with myeloproliferative neoplasms].
Nephrotic Syndrome
A case of deep vein thrombosis in idiopathic nephrotic syndrome with resistance to activated protein C.
Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome.
The factor V Leiden mutation and risk of renal vein thrombosis in patients with nephrotic syndrome.
Nervous System Diseases
Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier.
Neuralgia
Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.
Neurodegenerative Diseases
High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischemia in rats.
Neuroinflammatory Diseases
Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons.
Nocardia Infections
Multiple medical problems following agent orange exposure.
Non-alcoholic Fatty Liver Disease
Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases.
Obesity
Activated protein C levels in obesity and weight loss influence.
Obesity and activated protein C resistance.
Oligohydramnios
Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women.
Onychomycosis
Multiple medical problems following agent orange exposure.
Optic Nerve Diseases
Activated protein C resistance in anterior ischaemic optic neuropathy.
Optic Neuropathy, Ischemic
Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature.
Ischemic optic neuropathy and giant cell arteritis.
[Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients < 60 years of age]
Osteoarthritis
Matrix metalloproteinase (MMP)-2, MMP-9 and MMP-13 are activated by Activated Protein C (APC) in human osteoarthritic cartilage chondrocytes.
Osteonecrosis
Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.
Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.
Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens.
Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia.
Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis.
Ovarian Hyperstimulation Syndrome
Activated protein C and the ovarian hyperstimulation syndrome: Possible therapeutic implications.
Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome.
Ovarian Neoplasms
Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.
Identification of key genes for guiding chemotherapeutic management in ovarian cancer using translational bioinformatics.
Paper based immunosensing of ovarian cancer tumor protein CA 125 using novel nano-ink: A new platform for efficient diagnosis of cancer and biomedical analysis using microfluidic paper-based analytical devices (?PAD).
Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway.
Overweight
A family history of type 2 diabetes is associated with lower sensitivity to activated protein C in overweight and obese premenopausal women.
Individual risk assessment of thrombosis in pregnancy.
Pancreatitis
Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial.
Activated Protein C Improves the Severity of Severe Acute Pancreatitis via Up-Regulating the Expressions of Endothelial Cell Protein C Receptor and Thrombomodulin.
Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...
Activated protein C retards recovery from coagulopathy in severe acute pancreatitis.
Activated protein C, an anticoagulant polypeptide, ameliorates severe acute pancreatitis via regulation of mitogen-activated protein kinases.
Activated Protein C-Protein C Inhibitor Complex, Activation Peptide of Carboxypeptidase B and C-Reactive Protein as Predictors of Severe Acute Pancreatitis.
Administration of human recombinant activated protein C is not associated with pancreatic parenchymal haemorrhage in L-arginine-induced experimental acute pancreatitis.
Correction: The effect of activated protein C on experimental acute necrotizing pancreatitis.
Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis.
Levels of protein C and activated protein C: what do they mean?
Recombinant human activated protein C (Xigris) attenuates murine cerulein-induced acute pancreatitis via regulation of nuclear factor ?B and apoptotic pathways.
Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence.
Release and activity of histone in diseases.
The effect of activated protein C on experimental acute necrotizing pancreatitis.
Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial.
Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis.
Use of activated protein C has no avail in the early phase of acute pancreatitis.
[Pathogenesis and treatment of hemocoagulation disorders in an acute necrotic pancreatitis]
Pancreatitis, Acute Necrotizing
Correction: The effect of activated protein C on experimental acute necrotizing pancreatitis.
The effect of activated protein C on experimental acute necrotizing pancreatitis.
Use of activated protein C has no avail in the early phase of acute pancreatitis.
Pancreatitis, Graft
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Paraproteinemias
Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.
Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Thrombosis and Hemostatic Abnormalities in Hematological Malignancies.
Peripheral Arterial Disease
Inherited thrombophilia.
Peripheral Vascular Diseases
Activated protein C resistance in patients with peripheral vascular disease.
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease.
Peritonitis
Effect of activated protein C on secretory activity of rat peritoneal mast cells.
Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis.
Release and activity of histone in diseases.
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
Phlebitis
[Pulmonary embolism in patients using estrogen-progestagen contraceptives]
plasmin deficiency
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Pneumonia
A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis.
Activated protein C inhibits the expression of platelet-derived growth factor in the lung.
Activated protein C protection from lung inflammation in endotoxin-induced injury.
Adjunctive Therapies in Severe Pneumonia in Critical Care Patients.
CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS.
Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury.
Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment.
Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice.
Inhaled activated protein C: a new therapy for the prevention of ventilator-induced lung injury?
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats.
Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.
Progressive and nonresolving pneumonia.
Recent advances in community-acquired pneumonia: inpatient and outpatient.
Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats.
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis.
Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation.
[Identification of patients suitable for therapy with activated Protein C]
Pneumonia, Bacterial
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
Pneumonia, Pneumococcal
New modalities in treating pneumococcal pneumonia.
Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.
Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia.
The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis.
Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia.
Polycystic Ovary Syndrome
Are women with polycystic ovary syndrome resistant to activated protein C?
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Polycythemia Vera
Activated Protein C Resistance in Polycythemia Vera.
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombotic disease in the myeloproliferative neoplasms.
Postphlebitic Syndrome
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
Pre-Eclampsia
A comparative study of the protein C system in mother's blood, cord blood and amniotic fluid.
Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial.
Activated protein C for preeclampsia: tailoring the disease to the therapy.
Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity?
Activated protein C resistance and adverse pregnancy outcome.
Activated protein C resistance in preeclampsia.
Activated protein C resistance in Turkish women with severe preeclampsia.
Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation.
Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia.
Congenital thrombophilia associated to obstetric complications.
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents.
Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy.
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.
Individual risk assessment of thrombosis in pregnancy.
Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin.
Performance of a novel test to quantify activated protein C resistance in women with a history of pre-eclampsia.
Preeclampsia is associated with a reduced response to activated protein C.
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
The factor V Leiden mutation may predispose women to severe preeclampsia.
The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance.
Thrombophilic mutations in pre-eclampsia and pregnancy-induced hypertension.
Underlying disorders associated with severe early-onset preeclampsia.
[Deep venous thrombosis in pregnant women]
[Genetic trombophilia and markers of endotelial activation in patients with preeclampsia]
[Occurrence of gene mutations in factor V Leiden, prothrombin and methylenetetrahydrofolate reductase in patients with pre-eclampsia]
[Pathophysiology and clinical manifestations in pre-eclampsia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Pregnancy Complications
Activated protein C resistance and pregnancy complications.
Evolution of Factor V Leiden.
Postnatal screening for thrombophilia in women with severe pregnancy complications.
Pressure Ulcer
Activated protein C to heal pressure ulcers.
Priapism
[Priapism and activated protein C resistance]
protein c (activated) deficiency
Cardiopulmonary bypass for a coronary artery bypass graft patient with heterozygous protein C deficiency and protein S deficiency.
Laboratory investigation of hypercoagulability.
Protein C pathway impairment in nonsymptomatic cigarette smokers.
[Inherited thrombophilia]
[Laboratory identification of blood hypercoagulability]
Protein C Deficiency
A case of purpura fulminans is caused by homozygous delta8857 mutation (protein C-nagoya) and successfully treated with activated protein C concentrate.
A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency.
A preliminary pilot study of treatment of thrombophilia and hypofibrinolysis and amelioration of the pain of osteonecrosis of the jaws.
Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.
Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden.
Activated protein C concentrate: a new tool for the treatment of acute thromboembolism in patients with congenital protein C deficiency.
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Air travel-associated venous thromboembolism.
Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients.
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Cardiopulmonary bypass for a coronary artery bypass graft patient with heterozygous protein C deficiency and protein S deficiency.
Clinical and ethnic characteristics of stroke in an Israeli population: a study in a community hospital population.
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway.
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy.
Heritable coagulopathies in pregnancy.
High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia.
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Hypercoagulability test strategies in the protein C and protein S pathway.
Idiopathic intracranial hypertension and anticardiolipin antibodies.
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy.
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Laboratory investigation of hypercoagulability.
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Mesenteric vein thrombosis associated with primary cytomegalovirus infection: a case report.
Myocardial infarction and normal coronary arteries: the experience of the cardiology department of sfax, Tunisia.
Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Plasma protein S deficiency in familial thrombotic disease.
Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency.
Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation.
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
ProC Global: the first functional screening assay for the complete protein C pathway.
Protein C antigen levels in major abdominal surgery: relationships to deep vein thrombosis, malignancy and treatment with stanozolol.
Protein C deficiency.
Protein C pathway impairment in nonsymptomatic cigarette smokers.
Rational Design of Protein C Activators.
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach.
Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis.
Six missense mutations associated with type I and type II protein C deficiency and implications obtained from molecular modelling.
Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate.
Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C.
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
The use of direct oral anticoagulants in inherited thrombophilia.
Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis.
Thrombophilia in children with cystic fibrosis.
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Vascular surgical society of great britain and ireland: prevalence and significance of thrombophilia in patients with intermittent claudication
[Inherited thrombophilia]
[Laboratory identification of blood hypercoagulability]
[Pathophysiology and clinical manifestations in pre-eclampsia]
[Perioperative management of a patient with purpura fulminans syndrome due to protein C deficiency]
[Pulmonary embolism in patients using estrogen-progestagen contraceptives]
[Risk factors of venous thromboembolism]
[The protein C inhibitory system]
[Thrombosis of the cerebral venous sinuses: a description of its clinical features, risk factors and treatment in a hospital of Colombia]
Protein Deficiency
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colombian Patients.
Protein S Deficiency
A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis.
Activated protein C resistance and deficiencies of antithrombin III, protein C or protein S and the risk of thromboembolic disease in users of oral contraceptives.
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Diagnostic approach to hypercoagulable states.
Early loss of renal transplants in patients with thrombophilia.
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Familial thrombophilia: clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency.
Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome.
Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency.
Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke?
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
Heritable coagulopathies in pregnancy.
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Hypercoagulability test strategies in the protein C and protein S pathway.
Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.
Inherited prothrombotic states and ischaemic stroke in childhood.
Inherited thrombophilia and pregnancy.
Inherited thrombophilia: an update.
Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.
Ischemic colitis revisited: a prospective study identifying hypercoagulability as a risk factor.
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Preeclampsia in women with Inheritable Thrombophilia: the FRUIT-RCT.
Maternal and paternal thrombophilia: risk factors for perinatal mortality.
N-Terminal domain linkage modulates the folding properties of protein S epidermal growth factor-like modules.
No correlation between activated protein C resistance and free flap failures in 100 consecutive patients.
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy.
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
ProC Global: the first functional screening assay for the complete protein C pathway.
Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.
Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S.
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Retinal vascular occlusion and deficiencies in the protein C pathway.
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study.
Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
The clinical spectrum of acute renal infarction.
The molecular basis of inherited thrombophilia.
The prevalence of thrombophilia in patients with chronic venous leg ulceration.
The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
The use of direct oral anticoagulants in inherited thrombophilia.
Thrombophilia in children with cystic fibrosis.
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Thrombophilic factors in chronic thromboembolic pulmonary hypertension.
Underlying disorders associated with severe early-onset preeclampsia.
Vascular surgical society of great britain and ireland: prevalence and significance of thrombophilia in patients with intermittent claudication
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]
[Congenital deficiencies of natural anticoagulant systems responsible for recurrent thromboembolism]
[Inherited thrombophilia.]
[Risk factors of venous thromboembolism]
[Thrombophilia factors as inducers of retinal vascular occlusion]
[Thrombophilia in a family with resistance to activated protein C and protein S deficiency]
[Thrombophilic states]
Pulmonary Edema
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
Pulmonary Embolism
A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C.
Activated protein C and pulmonary embolism.
Activated protein C resistance is uncommon in sudden death due to pulmonary embolism.
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome.
Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.
Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism.
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Ischemic colitis, pulmonary embolism, and right atrial thrombosis in a patient with inherited resistance to activated protein C.
Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.
Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.
Resistance to activated protein C in an unselected population of patients with pulmonary embolism.
Screening for a prothrombotic diathesis in patients attending family planning clinics.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Three-year evaluation of late breast reconstruction with a free transverse rectus abdominis musculocutaneous flap in a county hospital in Sweden: a retrospective study.
Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
[Activated protein C resistance and deep venous thrombosis in pregnancy]
[Pulmonary embolism disclosing activated protein C resistance]
[Pulmonary thromboembolism in a female with resistance to activated protein C]
Pulmonary Fibrosis
High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis.
Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels.
Reply: Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels.
Purpura Fulminans
A case of purpura fulminans is caused by homozygous delta8857 mutation (protein C-nagoya) and successfully treated with activated protein C concentrate.
Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.
Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy.
Massive soft tissue infections: necrotizing fasciitis and purpura fulminans.
Neonatal purpura fulminans in association with factor V R506Q mutation.
Plasma exchange as a source of protein C for acute onset protein C pathway failure.
Pneumococcal purpura fulminans successfully treated with activated protein C.
Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis.
Treatment of acute infectious purpura fulminans with activated protein C.
[Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans]
[Sepsis-associated coagulation disorders]
Purpura, Thrombotic Thrombocytopenic
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Pyoderma Gangrenosum
Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum.
Renal Insufficiency
Tissue factor coagulation pathway and blood cells activation state in renal insufficiency.
Reperfusion Injury
A Friend in Need: Activated Protein C Stabilizes YB-1 during Renal Ischemia Reperfusion Injury.
Activated Protein C Ameliorates Renal Ischemia-Reperfusion Injury by Restricting Y-Box Binding Protein-1 Ubiquitination.
Activated protein C attenuates acute ischaemia reperfusion injury in skeletal muscle.
Activated protein C improves left ventricular remodelling after ischemia-reperfusion injury in rats.
Activated Protein C in Ischemia-Reperfusion Injury After Experimental Lung Transplantation.
Activated protein C in the cardioplegic solution on a porcine model of coronary ischemia-reperfusion has deleterious hemodynamic effects.
Activated protein C prevents deleterious effects of remote reperfusion injury caused by intestinal ischemia on wound healing in the left colonic anastomoses: an experimental study in the murine model.
Activated protein C prevents methylglyoxal-induced endoplasmic reticulum stress and cardiomyocyte apoptosis via regulation of the AMP-activated protein kinase signaling pathway.
Activated protein C protects myocardium via activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart.
Activated protein C: an emerging therapeutic agent in the prevention of ischemia-reperfusion injury.
Beyond sepsis: activated protein C and ischemia-reperfusion injury.
Comparative Study on the Cytoprotective Effects of Activated Protein C Treatment in Nonsteatotic and Steatotic Livers under Ischemia-Reperfusion Injury.
Cytoprotective activated protein C averts Nlrp3 inflammasome induced ischemia reperfusion injury via mTORC1 inhibition.
Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice.
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Neuroprotective effects of activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 receptor, and its downstream signal phosphorylated serine-threonine kinase after spinal cord ischemia in rabbits.
The Effect of Activated Protein C on Attenuation of Ischemia-Reperfusion Injury in a Rat Muscle Flap Model.
Respiratory Distress Syndrome
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome.
Activated Protein C has No Effect on Pulmonary Capillary Endothelial Function in Septic Patients with Acute Respiratory Distress Syndrome: Association of Endothelial Dysfunction with Mortality.
Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome.
Activated protein C nebulization in severe late acute respiratory distress syndrome.
Alveolar dead-space response to activated protein C in acute respiratory distress syndrome.
Can we reduce mortality in sepsis?
Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis.
Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock.
Evidence lost to treatment of critically-ill patients?
Gonococcal septic shock, acute respiratory distress syndrome, and multisystem organ failure: a case report.
Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome.
Nebulized activated protein C in a paediatric patient with severe acute respiratory distress syndrome secondary to H1N1 influenza.
Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.
Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.
Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial.
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Toronto Critical Care Medicine Symposium, 18-20 October 2001, Canada: research breakthroughs are not enough.
Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review.
[New therapeutic strategies in severe sepsis and septic shock]
[Protocol of the management of patients with severe sepsis and septic shock].
Respiratory Insufficiency
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Retinal Artery Occlusion
Central retinal artery occlusion in a patient homozygous for factor V Leiden.
Central retinal artery occlusion in a young child secondary to resistance to activated protein C.
Retinal Neovascularization
Peripheral retinal neovascularization and retinal vascular occlusion associated with activated protein C resistance.
Retinal Vein Occlusion
Activated protein C and retinal vein occlusion.
Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results.
Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion.
Activated protein C resistance in central retinal vein occlusion.
Activated protein C resistance in patients with central retinal vein occlusion.
Activated protein C resistance in young adults with central retinal vein occlusion.
Activated protein C resistance is a risk factor for central retinal vein occlusion.
Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults.
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion.
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.
Central retinal vein thrombosis associated with resistance to activated protein C.
Diagnosis of activated protein C resistance in retinal vein occlusion.
Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
High prevalence of resistance to APC in young patients with retinal vein occlusion.
Long-term outcomes of intravitreal activated protein C injection for ischemic central retinal vein occlusion: an extension trial.
Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion.
Reperfusion of large ischemic areas associated with central retinal vein occlusion: a potential novel treatment with activated protein C.
Risk factors in central retinal vein occlusion an activated protein C resistance.
Risk factors in central retinal vein occlusion and activated protein C resistance.
Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion.
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]
[Retinal vein occlusion and resistance to activated protein C]
Rhinitis
Activated protein C modulates the proinflammatory activity of dendritic cells.
Sagittal Sinus Thrombosis
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Sarcoma
Acquired activated protein C resistance in sarcoma patients.
Sarcoma, Kaposi
[Activated C protein resistance manifested by cutaneous necrosis after interferon alpha injection: case report]
Scleroderma, Systemic
High prevalence of activated protein C resistance in patients with systemic sclerosis.
Scrub Typhus
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Sepsis
A case series of drotrecogin alfa (activated) in lung transplant recipients.
A clinically applicable porcine model of septic and ischemia/reperfusion-induced shock and multiple organ injury.
A long-term follow-up study investigating health-related quality of life and resource use in survivors of severe sepsis: comparison of recombinant human activated protein C with standard care.
A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.
A plethora of angiopoietin-2 effects during clinical sepsis.
A Systematic Summary of Systematic Reviews on Anticoagulant Therapy in Sepsis.
Activated protein C (Xigris(R)) treatment in sepsis: a drug in trouble.
Activated protein C (Xigris) for severe sepsis.
Activated Protein C Alters Inflammation and Protects Renal Function in Sepsis.
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis.
Activated protein C and sepsis.
Activated protein C and septic shock: A propensity-matched cohort study.
ACTIVATED PROTEIN C ATTENUATES MICROVASCULAR INJURY DURING SYSTEMIC HYPOXIA.
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Activated protein C for sepsis.
Activated protein C for severe sepsis.
Activated protein C for the treatment of severe sepsis.
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Activated Protein C Improves Macro and Microvascular Reactivity in Human Severe Sepsis and Septic Shock.
Activated protein C improves survival in severe sepsis patients with elevated troponin.
Activated protein C in a pregnant patient with severe sepsis.
Activated protein C in patients with septic shock: a consecutive case series.
Activated protein C in sepsis and beyond: update 2006.
Activated protein C in sepsis.
Activated protein C in sepsis: a critical review.
Activated protein C in sepsis: down but not out, yet.
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.
Activated protein C in sepsis: tightening pulmonary endothelial cells?
Activated protein C in septic shock: a propensity-matched analysis.
Activated protein C in severe sepsis.
Activated protein C in the treatment of sepsis.
Activated protein C in toxic shock syndrome: a case report.
Activated protein C induces the release of microparticle-associated endothelial protein C receptor.
Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions.
Activated protein C inhibits high mobility group box 1 signaling in endothelial cells.
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.
Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes.
Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans.
Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes.
Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
Activated protein C levels in patients with severe sepsis: rebuttal.
Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.
Activated protein C modulates chemokine response and tissue injury in experimental sepsis.
Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes.
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.
Activated protein C protects vascular endothelial cells from apoptosis in malaria and in sepsis.
Activated protein C restores hepatic microcirculation during sepsis by modulating vasoregulator expression.
Activated protein C signals through the thrombin receptor PAR1 in endothelial cells.
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice.
Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes.
Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function.
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.
Activated protein C versus protein C in severe sepsis.
Activated protein C was cost-effective for prolonging survival in a subgroup of patients with severe sepsis.
Activated protein C: controversy and hope in the treatment of sepsis.
Activated protein C: cost-effective or costly?
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.
Activated protein C: the cure for sepsis - again?
Activated recombinant human protein C does not attenuate recruitment of neutrophils in rat models of acute inflammation.
Activated recombinant protein C in septic shock early after liver transplantation: a case report.
Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Adjunct therapy for sepsis: how early?
Adjunctive corticosteroid therapy in pediatric severe sepsis: Observations from the RESOLVE study*
Adjunctive Therapies in Severe Pneumonia in Critical Care Patients.
Advances in pathogenesis and management of sepsis.
Advances in sepsis therapy.
Advances in Sepsis Treatment.
Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses.
Advances in understanding sepsis.
Adventure of Recombinant Human Activated Protein C in Sepsis and New Treatment Hopes on the Horizon.
Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.
alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
Alterations in the human lung proteome with lipopolysaccharide and activated protein C.
Alterations of leptin in the course of inflammation and severe sepsis.
Alternative treatments for disseminated intravascular coagulation.
Alveolar dead-space response to activated protein C in acute respiratory distress syndrome.
An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.
An economic evaluation of activated protein C treatment for severe sepsis.
An update on activated protein C (xigris) in the management of sepsis.
Anti-inflammatory strategies for the treatment of sepsis.
Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.
Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan.
Anticoagulant therapy in acute lung injury: a useful tool without proper operating instruction?
Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation.
Antithrombotic Agents in the Management of Sepsis.
Antithrombotic agents in the treatment of severe sepsis.
Assessing the use of activated protein C in the treatment of severe sepsis.
Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury.
Best evidence in anesthetic practice: prevention: recombinant human activated protein C reduces mortality in severe sepsis.
Beyond sepsis: activated protein C and heat stroke.
Beyond sepsis: activated protein C and ischemia-reperfusion injury.
Brief report: tuberculosis sepsis and activated protein C.
Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Catastrophic antiphospholipid syndrome and Kikuchi-Fujimoto disease: the first case reported.
Clinical Acute Lung Injury and Acute Respiratory Distress Syndrome.
Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis.
Clinical expert round table discussion (session 3) at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis.
Clinical impact of novel anticoagulation strategies in sepsis.
Coagulation in sepsis: all bugs bite equally.
Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C.
Coagulation inhibition for sepsis.
Coagulation inhibitors in the treatment of sepsis.
Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.
Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis.
Compliance With a Sepsis Bundle and Its Effect on Intensive Care Unit Mortality in Surgical Septic Shock Patients.
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome.
Controversial treatment of a victim of severe head injury complicated by septic shock and acute respiratory distress syndrome.
Controversies in the treatment of sepsis.
Copper inhibits activated protein C: protective effect of human albumin and an analogue of its high-affinity copper-binding site, d-DAHK.
Cost-effectiveness of activated protein C in real-life clinical practice.
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.
Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
Critical points for sepsis management at the patient bedside.
CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS.
Current advances in sepsis and septic shock with particular emphasis on the role of insulin.
Current concepts in the role of the host response in Neisseria meningitidis septic shock.
Current issues regarding the use of drotrecogin alfa (activated).
Current role of activated protein C therapy for severe sepsis and septic shock.
Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis.
Determinants of mortality in patients with severe sepsis.
Disseminated intravascular coagulation in sepsis.
Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Drotrecogin alfa (activated) did not reduce mortality at 28 or 90 days in patients with septic shock.
Drotrecogin alfa (activated) for severe sepsis.
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.
Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis.
Drotrecogin alfa (activated).
Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.
Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Drotrecogin Alfa (Activated): does current evidence support treatment for any patients with severe sepsis?
Drotrecogin alfa (activated): real-life use and outcomes for the UK.
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
Drotrecogin alfa.
Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Drotrecogin alpha (activated): the treatment for severe sepsis?
Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling.
Effect of Drotrecogin alfa (activated) on platelet receptor expression in vitro.
Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
Effect of recombinant human activated protein C on apoptosis-related proteins.
Effect of sepsis therapies on health-related quality of life.
Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Effectiveness of human recombinant activated protein C for severe sepsis and septic shock in adult and pediatric patients: randomized clinical trial versus nonrandomized study.
Effectiveness of treatments for severe sepsis: data from the bundle implementation programs.
Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury.
Effects of activated protein C on post cardiac arrest microcirculation: an in vivo microscopy study.
Effects of activated protein C on the mesenteric microcirculation and cytokine release during experimental endotoxemia: [Effets de la proteine C activee sur la microcirculation mesenterique et la liberation de cytokines durant une endotoxemie experimentale].
Effects of recombinant human activated protein C in human models of endotoxin administration.
Effects of recombinant human activated protein C on the coagulation system: a study with rotational thromboelastometry.
Efficacy and effectiveness of recombinant human activated protein C in severe sepsis of adults.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis.
Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality.
Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge.
Endogenous protein C activation in patients with severe sepsis.
Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways.
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C.
Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.
Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells.
Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign.
Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.
Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Evidence lost to treatment of critically-ill patients?
Evidence-based management of critically ill patients: analysis and implementation.
Evolution of treatments for patients with acute lung injury.
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Fulminant sepsis/meningitis due to Haemophilus influenzae in a protein C-deficient heterozygote treated with activated protein C therapy.
Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group.
Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis.
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.
Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis.
Guidelines for the diagnosis and management of disseminated intravascular coagulation.
Hemodynamic effects of recombinant human activated protein C in patients with septic shock.
Heparin: the cheap alternative for immunomodulation in sepsis?
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
How to ENHANCE our knowledge of activated protein C during pediatric sepsis trials: pediatric versus adult trials.
Human models of endotoxemia and recombinant human activated protein C.
Human recombinant activated protein C for severe sepsis.
Human recombinant activated protein C in meningococcal sepsis.
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.
Hyper-antithrombotic, non-cytoprotective Glu149Ala-activated protein C mutant.
Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).
Immunomodulation in sepsis: state of the art and future perspective.
Increased activated protein C to protein C ratio in sepsis and cirrhosis.
Increased coagulation and suppressed generation of activated protein C in aged mice during intra-abdominal sepsis.
Infection/inflammation and hemostasis.
Inflammation and coagulation. An overview.
Inflammation and coagulation: implications for the septic patient.
Inhaled activated protein C protects mice from ventilator-induced lung injury.
Intra-abdominal infections.
Is There NO Treatment For Severe Sepsis?
Is tri-iodothyronine a better choice than activated protein C in sepsis treatment?
Kinetics of immune parameters in a patient with sepsis caused by Streptococcus pyogenes treated with activated protein C.
Levels of protein C activity and clinical factors in early phase of pediatric septic shock may be associated with the risk of death.
Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates.
Low plasma protein C values predict mortality in low birth weight neonates with septicemia.
Managing septic shock.
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.
Mathematical models of the acute inflammatory response.
Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C.
Mediators of systemic inflammatory response syndrome and the role of recombinant activated protein C in sepsis syndrome.
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis.
Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.
Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein C.
Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.
Microparticles as biological vectors of activated protein C treatment in sepsis.
Modulation of monocyte function by activated protein C, a natural anticoagulant.
Modulation of sepsis outcome with variants of activated protein C.
Natural anticoagulant inhibitors: activated Protein C.
Neurological outcome and inflammation after cardiac arrest--effects of protein C in rats.
New additions to the intensive care armamentarium.
New and emerging therapies for sepsis.
New concepts in sepsis.
New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).
New modalities in treating pneumococcal pneumonia.
New players in the sepsis-protective activated protein C pathway.
New therapeutic options for patients with sepsis and disseminated intravascular coagulation.
Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia.
Only activated protein C treatment and not protein C has demonstrated an improvement in survival in severe sepsis.
Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
Overexpression of activated protein C hampers bacterial dissemination during pneumococcal pneumonia.
Overexpression of Activated Protein C is Detrimental During Severe Experimental Gram-Negative Sepsis (Melioidosis)*
PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury.
PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.
Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alpha (activated).
Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient.
Patients with severe sepsis vary markedly in their ability to generate activated protein C.
Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis.
Pharmacist intervention in activated protein C therapy for severe sepsis: influence on health and economic outcomes.
Pharmacologic treatment of acute renal failure in sepsis.
Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
Plasma exchange as a source of protein C for acute onset protein C pathway failure.
Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: a prospective cohort study.
Plasma soluble fibrin monomer complex is a useful predictor of disseminated intravascular coagulation in neonatal sepsis.
Pneumococcal purpura fulminans successfully treated with activated protein C.
Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses.
Postregistration trials: should we? How do we?
Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis.
Pro/Con debate of activated protein C in severe sepsis.
Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.
Prognostic value of platelet-derived growth factor in patients with severe sepsis.
Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1.
Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-{kappa}B, and ERK1/2 MAP kinases.
Protective effects of activated protein C in sepsis.
Protein C -1641A/-1654C haplotype is associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population.
Protein C and activated protein C in neonates with sepsis.
Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
Protein C as a surrogate end-point for clinical trials of sepsis.
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome.
Protein C pathway in sepsis.
Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis.
Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults.
Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients.
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
Recent developments in the treatment of sepsis.
Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia.
Recombinant activated protein C in pediatric sepsis.
Recombinant activated protein C in sepsis: endothelium protection or endothelium therapy?
Recombinant activated protein C induces dose-dependent changes in inflammatory mediators, tissue damage, and apoptosis in in vivo rat model of sepsis.
Recombinant activated protein C treatment improves tissue perfusion and oxygenation in septic patients measured by near-infrared spectroscopy.
Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes.
Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated).
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
Recombinant human activated protein C (Xigris).
Recombinant human activated protein C and strict glycemic control in sepsis: mutually exclusive strategies?
Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence.
Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?
Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep.
Recombinant human activated protein C for severe sepsis in a neonate.
Recombinant human activated protein C for severe sepsis in neonates.
Recombinant human activated protein C for severe sepsis.
Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever.
Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach.
Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics?
Recombinant human activated protein C for use in severe sepsis.
Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis.
Recombinant human activated protein C in acute lung injury: what is the role of bronchial circulation?
Recombinant human activated protein C in sepsis: assessing its clinical use.
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.
Recombinant human activated protein C in severe sepsis.
Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.
Recombinant human activated protein C inhibits integrin-mediated neutrophil migration.
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis.
Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study.
Recombinant human activated protein C upregulates the release of soluble fractalkine from human endothelial cells.
Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
Recombinant human activated protein C.
Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.
Recombinant human activated protein C: current insights into its mechanism of action.
Redirection of the reaction between activated protein C and a serpin to the substrate pathway.
Reducing leukocyte trafficking preserves hepatic function after sepsis.
Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C.
Release and activity of histone in diseases.
Results of severe sepsis treatment program using recombinant human activated protein C in Poland.
rhAPC reduces the endothelial cell permeability via a decrease of contractile tensions induced by endothelial cells.
Risks and benefits of activated protein C treatment for severe sepsis.
Role of activated protein C in the pathophysiology of severe sepsis.
Role of Activated Protein C on Wound Healing Process in Left Colonic Anastomoses in the Presence of Intra-abdominal Sepsis Induced by Cecal Ligation and Puncture: An Experimental Study in the Rat.
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury.
Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis.
Role of microparticles in sepsis.
Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure.
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
Safety and efficacy of recombinant activated protein C for severe sepsis in abdominal organ recipients.
Safety of drotrecogin alfa (activated) in severe sepsis: Data from adult clinical trials and observational studies.
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Scientific and clinical challenges in sepsis.
Sepsis and ARDS: The Dark Side of Histones.
Sepsis and coagulation.
Sepsis and the role of activated protein C.
Sepsis as a model of SIRS.
Sepsis in the 21st century: recent definitions and therapeutic advances.
Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C.
Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis.
Severe sepsis and therapy with activated protein C.
Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.
Severe sepsis in a premature neonate: protein C replacement therapy.
Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis.
Standardization of Severe Sepsis Management: A Survey of Methodologies in Academic and Community Settings.
Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes.
Study of protein C, protein S, and antithrombin III in newborns with sepsis.
Substantiating the concerns about recombinant human activated protein C use in sepsis.
Successful treatment of severe sepsis with recombinant activated protein C during the third trimester of pregnancy.
Successful treatment of severe sepsis with recombinant human activated protein C in a patient with traumatic intracranial hemorrhage.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report.
The 26th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Tromso, Norway, 13-17 June 2001.
The anticoagulant action of recombinant human activated protein C (rhAPC, Drotrecogin alpha activated): comparison between cord and adult plasma.
The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome.
The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis.
The coagulation cascade in sepsis.
The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis.
The effect of activated protein C on experimental acute necrotizing pancreatitis.
The effect of inflammation on coagulation and vice versa.
The effect of plasma-derived activated protein C on leukocyte cell-death and vascular endothelial damage.
The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approach.
The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b.
The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.
The failure of biologics in sepsis: where do we stand?
The hematologic system as a marker of organ dysfunction in sepsis.
The implementation of new therapies for severe sepsis: some questions raised by "early goal-directed therapy, corticosteroid, and recombinant human activated protein c for the treatment of severe sepsis and septic shock in the emergency department".
The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients*.
The microcirculation is the motor of sepsis.
The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?
The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness.
The protein C pathway and sepsis.
The protein C pathway: implications for the design of the RESPOND study.
The role of heparin and allied compounds in the treatment of sepsis.
The Role of Protein C in Sepsis.
The role of protein C in sepsis.
The staging of sepsis: understanding heterogeneity in treatment efficacy.
The therapeutic challenge of Gram-negative sepsis: prolonging the lifespan of a scarce resource.
The use of activated protein C (drotrecogin alfa (activated)) in the treatment of severe sepsis.
The use of activated protein C in severe Plasmodium falciparum malaria.
The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies.
The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series.
The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: A new treatment approach.
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation].
Therapeutic intervention and targets for sepsis.
Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia.
Toronto Critical Care Medicine Symposium, 18-20 October 2001, Canada: research breakthroughs are not enough.
Tracking the microbes in sepsis: advancements in treatment bring challenges for microbial epidemiology.
Transcriptome analysis revealed unique genes as targets for the anti-inflammatory action of activated protein C in human macrophages.
Treatment of acute infectious purpura fulminans with activated protein C.
Treatment of chronic leg ulcers with topical activated protein C.
Treatment of sepsis and septic shock: is there a light at the end of the tunnel?
Treatment of sepsis with activated protein C.
Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response.
Treatment of severe sepsis secondary to mycobacterium avium-intracellulare with recombinant human activated protein C.
Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis.
Treatment with recombinant human activated protein C: one size does not fit all.
Troponin-I as a prognosticator of mortality in severe sepsis patients.
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569].
Unlike thrombin, protein C and activated protein C do not affect vascular tone.
Updates on role of human recombinant activated protein C in patients with sepsis and severe sepsis: Changed scenario after PROWESS SHOCK trial.
Urosepsis: from the intensive care viewpoint.
Use of activated protein C (drotrecogin alfa) in a patient with sepsis and respiratory failure on ultra high frequency jet ventilation.
Use of activated protein C in liver transplantation patients with septic shock.
Use of drotrecogin alfa (activated) in two patients with severe sepsis.
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Use of recombinant human activated protein C in nonmenstrual staphylococcal toxic shock syndrome.
Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study.
Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome.
Using transcutaneous oxygen pressure measurements as selection criteria for activated protein C use.
Vibrio vulnificus sepsis successfully treated with antibiotics, surgical debridement, and recombinant human activated protein C.
What is the role of recombinant activated protein C in the management of sepsis?
When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature.
Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review.
Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?
Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.
[Activated protein C and treatment of sepsis]
[Activated protein C in sepsis]
[Activated protein C, a protein at the crossroads between coagulation and inflammation].
[Activated protein C, coagulation, inflammation and treatment of severe sepsis]
[Activated protein C, coagulation, inflammation, and treatment of severe sepsis]
[Activated protein C--recent addition to therapy of sepsis]
[Activated proteine C]
[Advances in sepsis diagnosis and treatment]
[Application of recombinant human activated protein C with blood product administration and deep vein thrombosis in severe sepsis]
[Can we afford the costs of progress in intensive care medicine? A plea for a candid debate]
[Diagnosis and correction of thrombohemorrhagic complications in cardiosurgical patients in the early postoperative period].
[Disseminated intravascular coagulation syndrome and protein C]
[Drotrecogin alfa (activated): specific treatment for serious sepsis]
[Endothelial cells and coagulation abnormalities]
[Exogenous activated protein C in severe sepsis]
[Expensive modern therapy options in intensive care medicine in Germany-- are they being used? Results of a questionnaire]
[Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis]
[Highlighting the potential of heparin in the treatment of sepsis in view of failure of KyberSept and OPTIMIST projects]
[Human recombinant activated protein C in patients with severe sepsis and septic shock]
[Identification of patients suitable for therapy with activated Protein C]
[Identification of the patient with sepsis]
[Intensive care medicine -- update 2004]
[Invasive meningococcal disease--management and treatment].
[Mechanisms of action of recombinant human activated Protein C]
[Multiple organ failure. Mechanisms, clinical manifestations and treatment strategies]
[Non-infective treatments for septic shock]
[Novel treatment for severe sepsis: recombinant human protein C (RHAPC)]
[Peptide-agonist of protease-activated receptor (PAR 1), similar to activated protein C, promotesproliferation in keratinocytes and wound healing of epithelial layer.]
[Pharmacotherapy of sepsis].
[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]
[Protein C and coagulation in sepsis]
[Protocol of the management of patients with severe sepsis and septic shock].
[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis]
[Recombinant human activated protein C for sepsis: When should it be indicated?]
[Replacement therapy with protein C for meningococcal sepsis and fulminant purpura in pediatric patients]
[Respiratory and cadiovascular management of septic ALI-ARDS and shock]
[Role of coagulation in acute pulmonary lesion physiopathology. Parallelism with sepsis.]
[Sepsis diagnosis: hemostatic imbalance and role of activated protein C]
[Sepsis: infection and systemic inflammatory response]
[Septic shock: diagnosis and management]
[Severe sepsis treated with activated protein C]
[Should patients with severe sepsis be treated with activated protein C?]
[Surgical patient with severe sepsis: activated protein C and Surviving Sepsis Campaign]
[Therapeutic modulation of coagulation in sepsis]
[Thrombin generation in critical illnesses].
[Treatment of severe sepsis and multiple organ failure with activated protein C]
[Treatment of severe sepsis and septic shock]
[Two cases of severe sepsis successfully treated with activated protein C]
[Use of protein C concentrate in adult patients with severe sepsis and septic shock]
[Use of recombinant human activated protein C in severe sepsis in patient with a pericardial hemorrhagic collection after a recent cardiac surgery]
Shock, Cardiogenic
Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
Recombinant human activated protein C for severe sepsis in a neonate.
Shock, Septic
A dream deferred: the rise and fall of recombinant activated protein C.
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis.
Activated protein C and septic shock: A propensity-matched cohort study.
Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits.
Activated protein C downregulates p38 mitogen-activated protein kinase and improves clinical parameters in an in-vivo model of septic shock.
Activated protein C for the treatment of fulminant meningococcal septicaemia.
Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress.
Activated protein C improves LPS-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress.
Activated Protein C Improves Macro and Microvascular Reactivity in Human Severe Sepsis and Septic Shock.
Activated protein C in patients with septic shock: a consecutive case series.
Activated protein C in septic shock: a propensity-matched analysis.
Activated protein C in toxic shock syndrome: a case report.
An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C.
Authors' reply to Thomas et al.'s "Comment on 'Early treatment with activated protein C for meningococcal septic shock: case report and literature review' by Hasin et al.".
Beneficial effects of recombinant human activated protein C in a ewe model of septic shock.
Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock.
Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et al.
Comparative effects of recombinant human activated protein C and dexamethasone in experimental septic shock.
Compliance With a Sepsis Bundle and Its Effect on Intensive Care Unit Mortality in Surgical Septic Shock Patients.
Corticosteroids and human recombinant activated protein C for septic shock.
Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective.
Critical points for sepsis management at the patient bedside.
Current advances in sepsis and septic shock with particular emphasis on the role of insulin.
Current role of activated protein C therapy for severe sepsis and septic shock.
Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial.
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
Dexamethasone and recombinant human activated protein C improve myocardial function and efficiency during experimental septic shock.
Drotrecogin alfa (activated) did not reduce mortality at 28 or 90 days in patients with septic shock.
Drotrecogin alfa (activated) in adults with septic shock.
Drotrecogin alpha (activated) in neonatal septic shock.
Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
Early suspension of activated protein C treatment in septic patients after shock reversal.
Early treatment with activated protein C for meningococcal septic shock: case report and literature review.
Editors' comments on a new trial of activated protein C for persistent septic shock.
Effect of protein C and activated protein C on alveolar fibrin deposition and turnover in a piglet model of septic shock.
Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock.
Effectiveness of human recombinant activated protein C for severe sepsis and septic shock in adult and pediatric patients: randomized clinical trial versus nonrandomized study.
Effects of a novel anticoagulant compound (TV7130) in an ovine model of septic shock.
Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Emerging drugs for the treatment of sepsis.
Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
Erratum to: Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial.
Evidence lost to treatment of critically-ill patients?
Gonococcal septic shock, acute respiratory distress syndrome, and multisystem organ failure: a case report.
Hemodynamic effects of recombinant human activated protein C in patients with septic shock.
Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy.
Human recombinant activated protein C for severe sepsis.
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.
Hydrocortisone Compared with Placebo in Patients with Septic Shock Satisfying the Sepsis-3 Diagnostic Criteria and APROCCHSS Study Inclusion Criteria: A Post Hoc Analysis of the ADRENAL Trial.
Implementation of an evidence-based "standard operating procedure" and outcome in septic shock*
Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study.
Interactions between coagulation and inflammation.
Is There NO Treatment For Severe Sepsis?
Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation.
Low-dose corticosteroids in septic shock: Has the pendulum shifted?
Management of severe sepsis of abdominal origin.
MicroRNA expression following activated protein C treatment during septic shock.
Negative regulation of inducible nitric-oxide synthase expression mediated through transforming growth factor-beta-dependent modulation of transcription factor TCF11.
Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
Protein C preserves microcirculation in a model of neonatal septic shock.
Protein C zymogen in adults with severe sepsis or septic shock.
Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin.
Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients.
Recombinant activated protein C treatment improves tissue perfusion and oxygenation in septic patients measured by near-infrared spectroscopy.
Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock.
Recombinant Human Activated Protein C for Adults with Septic Shock: a Randomized Controlled Trial.
Recombinant human activated protein C for the treatment of severe sepsis and septic shock: a study protocol for incorporating observational evidence using a Bayesian approach.
Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report.
Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C.
Septic shock.
Spectrum of sepsis, mediators, source control and management of bundles.
Steroids in sepsis--more effective than activated protein C?
Successful treatment of life-threatening melioidosis with activated protein C and meropenem.
Successful treatment of septic shock and respiratory failure due to leptospirosis and scrub typhus coinfection with penicillin, levofloxacin, and activated protein C.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
The evolution of activated protein C plasma levels in septic shock and its association with mortality: A prospective observational study.
The implementation of new therapies for severe sepsis: some questions raised by "early goal-directed therapy, corticosteroid, and recombinant human activated protein c for the treatment of severe sepsis and septic shock in the emergency department".
The Next Generation of Sepsis Clinical Trial Designs: What Is Next After the Demise of Recombinant Human Activated Protein C?
The nexus between systemic inflammation and disordered coagulation in sepsis.
The role of glucocorticoids as adjunctive treatment for sepsis in the modern era.
The systemic inflammatory response syndrome.
The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature.
Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.
Treatment of impaired perfusion in septic shock.
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss.
Use of activated protein C in a case of paediatric septic shock.
Use of activated protein C in liver transplantation patients with septic shock.
Use of Drotrecogin Alpha (Recombinant Human Activated Protein C, rhAPC) in the Treatment of Severe Sepsis Induced by Graft Pancreatitis After Simultaneous Pancreas and Kidney Transplantation: A Case Report.
Use of recombinant human activated protein C in nonmenstrual staphylococcal toxic shock syndrome.
Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?
[Activated protein C and septic shock]
[Human recombinant activated protein C in patients with severe sepsis and septic shock]
[On activated protein C in septic shock]
[Potential benefits of non-anti-infective treatments of septic shock: a critical analysis of literature]
[Protocol of the management of patients with severe sepsis and septic shock].
[The new aspects of treatment of severe sepsis and septic shock]
[Toxic shock syndrome consecutive to the presence of vaginal tampon for menstruation regressive after early haemodynamic optimization and activated protein C infusion]
[Use of protein C concentrate in adult patients with severe sepsis and septic shock]
[Which therapeutic prospects in the septic syndrome?]
Sinus Thrombosis, Intracranial
Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis.
Cerebral sinus thrombosis in a young adult with activated protein C resistance and homosysteinaemia.
Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis.
Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis.
Skin Diseases
Activated Protein C Attenuates Systemic Lupus Erythematosus and Lupus Nephritis in MRL-Fas(lpr) Mice.
Novel Functions of the Anticoagulant Activated Protein C in Maintaining Skin Barrier Integrity to Impact on Skin Disease.
Skin Ulcer
Treatment of chronic leg ulcers with topical activated protein C.
Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum.
Spinal Cord Injuries
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes.
Neonatal brain injury and systemic inflammation: modulation by activated protein C ex vivo.
Neurological outcome and inflammation after cardiac arrest--effects of protein C in rats.
Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling.
NON-activated protein C as post-treatment after spinal cord compression injury in rats.
Protease-Activated Receptor-1 Supports Locomotor Recovery by Biased Agonist Activated Protein C after Contusive Spinal Cord Injury.
Retraction. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes.
The long-term effects of pre-treatment with activated protein C in a rat model of compression-induced spinal cord injury.
Spinal Cord Ischemia
Neuroprotective effects of activated protein C through induction of insulin-like growth factor-1 (IGF-1), IGF-1 receptor, and its downstream signal phosphorylated serine-threonine kinase after spinal cord ischemia in rabbits.
Stillbirth
How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
Stroke
Activated protein C (APC) resistance in young stroke patients.
Activated protein c can be used as a prophylactic as well as a therapeutic agent for heat stroke in rodents.
Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact.
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Activated Protein C Resistance Does Not Increase Risk for Recurrent Stroke or Death in Stroke Patients.
Activated protein C resistance in childhood stroke.
Activated protein C resistance in young African American patients with ischemic stroke.
Activated protein C therapy in a rat heat stroke model.
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.
Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.
Beyond sepsis: activated protein C and heat stroke.
Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants.
Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke.
Cytoprotective-selective activated protein C therapy for ischaemic stroke.
Emerging risk factors for stroke: Patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance.
Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients.
Evaluation of 3K3A-Activated Protein C to Treat Neonatal Hypoxic Ischemic Brain Injury in the Spiny Mouse.
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Functional recovery after embolic stroke in rodents by activated protein C.
Hemodynamic effects of recombinant human activated protein C in patients with septic shock.
Hemostatic markers with bolus versus prolonged heparin after carotid artery stenting.
Impairments of the protein C system and fibrinolysis in infection-associated stroke.
Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.
Multiple hemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia.
Neurological outcome and inflammation after cardiac arrest--effects of protein C in rats.
PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Physiological anticoagulants and activated protein C resistance in childhood stroke.
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Profile of prothrombotic factors in Indian children with ischemic stroke.
Prognosis after Cryptogenic Cerebral Ischemia in Patients with Coagulopathies.
Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.
Prothrombotic factors and the risk of acute onset non-cardioembolic stroke in young Asian Indians.
Release and activity of histone in diseases.
Resistance to activated protein C as a risk factor of stroke in a thalassemic patient.
Resistance to activated protein C as an etiology for stroke in a young adult: a case report.
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Response to activated protein C in subjects with and without dementia. The Dutch Vascular Factors in Dementia Study.
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
[The role of protein C in the pathogenesis of stroke]
Subarachnoid Hemorrhage
Inhibitory effect of activated protein C on cerebral vasospasm after subarachnoid hemorrhage in the rabbit.
Tachycardia, Ventricular
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Thrombocythemia, Essential
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
The transjugular intrahepatic portosystemic stent-shunt (TIPS) as rescue therapy for complete Budd-Chiari syndrome and portal vein thrombosis.
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
Thrombotic disease in the myeloproliferative neoplasms.
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
Thrombocytopenia
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.
Differences between adult and pediatric septic shock.
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Pregnancy associated coagulopathies in selected community hospitals in Southwest Nigeria.
Primary pulmonary artery sarcoma resembling chronic thromboembolic pulmonary disease.
Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin.
Use of activated protein C in liver transplantation patients with septic shock.
Venous gangrene of the upper extremity.
Thrombocytosis
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
Thromboembolism
A functional test for protein S activity in plasma.
A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice.
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Activated protein C (APC) resistance in Indian children with thromboembolism.
Activated protein C concentrate: a new tool for the treatment of acute thromboembolism in patients with congenital protein C deficiency.
Activated protein C resistance assay and factor V Leiden.
Activated Protein C Resistance in Polycythemia Vera.
APC resistance in childhood thromboembolism: diagnosis and clinical aspects.
Cross-comparison of the genome sequences from human, chimpanzee, Neanderthal and a Denisovan hominin identifies novel potentially compensated mutations.
Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance.
Hereditary thrombophilia and venous thromboembolism.
Individual risk assessment of thrombosis in pregnancy.
Intracardiac thrombus associated with resistance to activated protein C.
Phospholipid antibodies and resistance to activated protein C in women with thrombophilia.
Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.
Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.
The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
[Acute coronary syndrome following massive pulmonary embolism in a 81-year-old woman with thrombophilia]
[Multiple phlebothrombosis following cesarean section due to heterozygous factor V Leiden mutation detected post partum]
Thromboinflammation
COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.
Thrombophilia
A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
A case of hereditary thrombophilia in a Chinese Han patient with both antithrombin deficiency and Factor V Leiden: A case report and literature review.
A case report of recurrent vascular access thrombosis in a hemodialysis patient reveals combined acquired and inherited thrombophilia.
A chromogenic assay for activated protein C resistance.
A clinical audit of congenital thrombophilia investigation in tertiary practice.
A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G --> A mutation in the factor V gene.
A multi-laboratory assessment of congenital thrombophilia assays performed on the ACL TOP 50 family for harmonisation of thrombophilia testing in a large laboratory network.
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.
A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes.
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Acquired activated protein C resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an irish cohort of pregnant women.
Activated protein C anticoagulant system dysfunction and thrombophilia in Asia.
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Activated protein C resistance and factor V Leiden in Mexico.
Activated protein C resistance and lupus anticoagulant in pregnancy.
Activated protein C resistance and pregnancy loss.
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.
Activated protein C resistance in anterior ischaemic optic neuropathy.
Activated protein C resistance in deep venous thrombosis.
Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Activated protein C resistance, thrombophilia, and inflammatory bowel disease.
Activated protein C resistance: from phenotype to genotype and clinical practice.
Activated-protein-C resistance in cancer patients.
Activation of the protein C pathway in hereditary thrombophilia.
Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.
Advances in laboratory testing for thrombophilia.
Air travel-associated venous thromboembolism.
Allele-specific PCR amplification of factor V Leiden to identify patients at risk for thromboembolism.
An update on hypercoagulable disorders.
Analysis of blood clotting factor activities in canine Legg-Calvé-Perthes' disease.
Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro.
APC resistance in an elite female athlete.
APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
Are MPNs Vascular Diseases?
Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease.
Association between in vitro fertilization outcomes and inherited thrombophilias: a meta-analysis.
Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population.
Biological coagulation findings in third-generation oral contraceptives.
Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia.
Budd-Chiari syndrome associated with factor V leiden mutation: a report of 6 patients.
Budd-Chiari syndrome in a patient with factor V Leiden--successful treatment by TIPSS placement followed by liver transplantation.
Case Study of Pediatric Cerebral Sinus Venous Thrombosis Center of a Low Middle-Income Country.
Cerebral venous sinus thrombosis as presenting feature of ulcerative colitis.
Cerebral venous thrombosis and procoagulant factors--a case study.
Circulating activated protein C in thrombophilia carriers.
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Coagulopathies and osteonecrosis.
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Congenital thrombophilia associated to obstetric complications.
Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.
Diagnostic algorithm for thrombophilia screening.
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment.
Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?
Double hazard of thrombophilia and bleeding in leukemia.
Effect of platelet phospholipid exposure on activated protein C resistance: implications for thrombophilia screening.
Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications.
Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium.
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Epidemiology of factor V Leiden: clinical implications.
Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance.
Evaluation of recurrent thrombosis and hypercoagulability.
Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis.
Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke.
Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain.
Factor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based on the Spanish population.
Factor V Leiden and other coagulation factor mutations affecting thrombotic risk.
Factor V Leiden and post thromboembolic pulmonary hypertension.
Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia.
Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Factor V Leiden.
Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?
Familial antithrombin III deficiency in a Malay patient with massive thrombosis.
Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Familial thrombophilia: clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency.
Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR.
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK.
Heightened thrombin generation in individuals with resistance to activated protein C.
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Hereditary thrombophilia and venous thromboembolism.
Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.
Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss.
Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens.
High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors.
Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study.
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography.
Hypercoagulable State.
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Hypercoagulable states: molecular genetics to clinical practice.
Implementation of a cost-effective unlabeled probe high-resolution melt assay for genotyping of factor v leiden.
Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.
Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors.
Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors.
Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome.
Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.
Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
Inherited thrombophilia and pregnancy.
Inherited thrombophilia and pregnancy: the obstetric perspective.
Inherited Thrombophilia due to Factor V Leiden Mutation.
Inherited thrombophilia in unprovoked venous thromboembolism: Is non 'O' blood group an additional culprit in Indian patients?
Inherited thrombophilia: memorandum from a joint WHO/International Society on Thrombosis and Haemostasis meeting.
Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism.
Investigation of inherited thrombophilias in patients with pulmonary embolism.
Ischemic stroke subtypes and thrombophilia in young and elderly Brazilian stroke patients admitted to a rehabilitation hospital.
Issues concerning the laboratory investigation of inherited thrombophilia.
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway.
Laboratory testing for hypercoagulable disorders.
Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process.
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
Liver transplantation for acute Budd-Chiari syndrome in identical twin sisters with Factor V leiden mutation.
Long term anticoagulation (4-16 years) stops progression of idiopathic hip osteonecrosis associated with familial thrombophilia.
Low birthweight in relation to placental abruption and maternal thrombophilia status.
Low prevalence of the factor V Leiden among patients with ischemic stroke.
Low Response to Clopidogrel in Coronary Artery Disease.
Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Preeclampsia in women with Inheritable Thrombophilia: the FRUIT-RCT.
Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance.
Mechanical prosthetic heart valve thrombosis despite optimal anticoagulation in a patient with congenital thrombophilia (factor V Leiden).
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state.
Molecular genetics of venous thromboembolism.
Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Mutation screening for thrombophilia: two cases with factor V Cambridge without activated protein C resistance.
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk.
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin.
Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why.
Perinatal aspects of inherited thrombophilia.
Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis.
Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
Phospholipid antibodies and resistance to activated protein C in women with thrombophilia.
Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis.
Postmortem diagnosis of Factor V Leiden from paraffin wax embedded tissue.
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients.
Prevalence of resistence to activated protein C (APC-resistance) in blood donors in Kosovo.
Prevalence of the Factor V Leiden Mutation Arg534Gln in Western Region of Saudi Arabia: Functional Alteration and Association Study With Different Populations.
Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
Primary thrombophilia in Mexico IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients.
Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.
Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos.
Primary thrombophilia in Mexico: a single tertiary referral hospital experience.
Protein C pathway impairment in nonsymptomatic cigarette smokers.
Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
Rapid multiplex analysis for the factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia.
Relevance of Inherited Thrombophilia Screening in Adult Kidney Transplant Recipients.
Resistance to activated protein C (APC) in Indian patients of thrombophilia.
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Resistance to activated protein C as pathogenic factor of venous thromboembolism.
Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
Resistance to activated protein C in an unselected population of patients with pulmonary embolism.
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach.
Resistance to activated protein C: a major cause of inherited thrombophilia.
Resistance to activated protein C: role in venous and arterial thrombosis.
Risk factors and management of patients with upper limb deep vein thrombosis.
Risk factors for thrombophilia in young adults presenting with thrombosis.
Risk of myocardial infarction related to factor V Leiden mutation: a meta-analysis.
Risk of venous thromboembolism with third-generation oral contraceptives: A review.
Screening for thrombophilia: a laboratory perspective.
Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Simple and reliable factor V genotyping by PNA-mediated PCR clamping.
Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
Successful Living-Related Renal Allograft in a Recipient With Factor V Leiden Deficiency: A Case Report.
Testing for heredity hypercoagulability Activated protein C resistance.
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
The anticoagulant potential of the protein C system in hereditary and acquired thrombophilia: pathomechanisms and new tools for assessing its clinical relevance.
The blood coagulation mechanism in multiple myeloma.
The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
The impact of the factor V Leiden mutation on pregnancy.
The Leiden mutation and activated protein C resistance as risk factors for disseminated intravascular coagulation in acutely poisoned patients.
The molecular basis of inherited thrombophilia.
The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Thrombin generation in clinical conditions.
Thrombophilia and activated protein C resistance.
Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis.
Thrombophilia in patients with chronic venous leg ulcers-a study on patients with or without post-thrombotic syndrome.
Thrombophilia prevalence in patients seeking laparoscopic sleeve gastrectomy: extended chemoprophylaxis may decrease portal vein thrombosis rate.
Thrombophilia Profile in Budd-Chiari Syndrome and Splanchnic Vein Thrombosis: A Study from Western India.
Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws.
Thrombophilia: disorders predisposing to venous thromboembolism.
Thrombophilia: the discovery of activated protein C resistance.
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Thrombosis: new culprits in an old disorder.
Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
Use of L-asparaginase in childhood ALL.
Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants.
Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies.
Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells.
Vascular graft thrombosis secondary to activated protein C resistance: a case report and literature review.
Venous thromboembolism in multiple myeloma.
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Venous thrombosis and procoagulant factors in high-risk neuroblastoma.
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.
Venous thrombosis in a replanted finger with underlying factor V Leiden mutation.
Whole blood screening test for factor V Leiden using a Russell viper venom time-based assay.
[A new cause of familial thrombophilia: resistance to the effect of activated protein C]
[A new cause of hereditary thrombophilia: activated protein c resistance]
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]
[Activated protein C resistance as a cause of thrombophilia]
[Activated protein C resistance--a recently discovered hereditary thrombophilia]
[Activated protein C resistance: role in venous and arterial thrombosis]
[Diagnosis of thrombophilia based on coagulation and genetic studies]
[Early recurrent spontaneous abortion: How to take care in 2006?]
[Epidemiological risk factors for non-traumatic osteonecrosis]
[Factor V leiden and venous thromboembolism in a woman taking second generation oral contraceptives: a case report]
[Familial thrombophilia due to resistance to activated protein C]
[Hereditary thrombophilia in free microvascular flaps--a case report]
[Initial experience in the diagnosis of thrombophilia due to activated protein C resistance]
[Intravenous recombinant tissue plasminogen activator in an 18-week pregnant woman with embolic stroke]
[Laboratory testing for venous thromboembolism]
[National evaluation of the diagnosis of activated protein C resistance]
[New causes of inherited thrombophilia]
[Occurrence of gene mutations in factor V Leiden, prothrombin and methylenetetrahydrofolate reductase in patients with pre-eclampsia]
[Resistance to activated protein C. The most common cause of familial thrombophilia]
[Resistance to activated protein C: a new cause of hypercoagulability]
[Risk factors of venous thromboembolism]
[Risk of thrombosis with oral contraceptives: value of a thrombophilia screening test]
[Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives]
[Study of activated protein C resistance(APC-R) and FV Leiden in healthy blood donors and patients with thrombosis]
[Thrombophilia in a family with resistance to activated protein C and protein S deficiency]
[Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment]
Thrombophlebitis
Activated protein C resistance and its correlation with thrombophlebitis in Behçet's disease.
Thrombosis
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
A case of deep vein thrombosis in idiopathic nephrotic syndrome with resistance to activated protein C.
A clinical audit of congenital thrombophilia investigation in tertiary practice.
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility.
Acquired activated protein C resistance and thrombosis in multiple myeloma patients.
Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis.
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Activated protein C (APC) resistance in indian juvenile deep vein thrombosis (DVT)
Activated protein C accelerates venous thrombus resolution through heme oxygenase-1 induction.
Activated protein C and sepsis.
Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces.
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium.
Activated protein C in sepsis and beyond: update 2006.
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
Activated protein C inhalation: a novel therapeutic strategy for acute lung injury.
Activated protein C inhibits thrombus formation in a system with flowing blood.
Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death.
Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
Activated protein C resistance (APCR) and placental fibrin deposition.
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states.
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.
Activated protein C resistance and adverse pregnancy outcome.
Activated protein C resistance and deficiencies of antithrombin III, protein C or protein S and the risk of thromboembolic disease in users of oral contraceptives.
Activated protein C resistance and false type 2 protein C deficiency detected after multiple shunt failures in a patient with hydrocephalus.
Activated protein C resistance and inherited thrombosis.
Activated protein C resistance and pregnancy loss.
Activated protein C resistance and the factor V Leiden mutation in children with thrombosis.
Activated protein C resistance and thrombosis.
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
Activated protein C resistance can be associated with recurrent fetal loss.
Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Activated protein C resistance in antiphospholipid thrombosis syndrome.
Activated protein C resistance in cord blood from healthy and complicated newborns.
Activated protein C resistance in pediatric inflammatory bowel disease.
Activated Protein C Resistance in Polycythemia Vera.
Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
Activated protein C resistance--a major risk factor for thrombosis.
Activated protein C resistance: a study among 60 thromboembolic patients in the Singapore population.
Activated protein C resistance: What have we learned now that the dust has settled?
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke.
Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance.
An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.
An underestimated combination of opposites resulting in enhanced thrombotic tendency.
Antenatal screening for factor V Leiden mutation: a critical appraisal.
Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids.
Anti-Domain I ?2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study.
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation.
Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model.
Antithrombotic and anticoagulant effects of wild type and Gla-domain mutated human activated protein C in rats.
Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis.
Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
Are women with polycystic ovary syndrome resistant to activated protein C?
Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
Association of increased C-Reactive Protein and hypocomplementemia with risk factors for thrombosis in women who have susceptibility for poor gestational outcome; importance of preconceptional counseling.
Association of primary antiphospholipid syndrome with inherited activated protein C resistance.
Association of resistance to activated protein with the presence of Leiden and Cambridge Factor V mutations in Mexican patients with primary thrombophilia.
Association of severe haemophilia A and factor V Leiden: report of three cases.
Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.
Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.
Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies.
Biomolecular surface engineering of pancreatic islets with thrombomodulin.
Blockade of protein C activation reduces microvascular surgical blood loss.
Blocking endothelial protein C receptor (EPCR) accelerates thrombus development in vivo.
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V.
Cardiac manifestations in the antiphospholipid syndrome.
Central retinal vein thrombosis associated with resistance to activated protein C.
Central venous thrombosis after cardiac operations in children.
Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation.
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Clinical sciences and orthopaedics: case report homozygous APC resistance in an elite athlete.
Co-segregation of thrombosis with the factor V Q506 mutation in an extended family with resistance to activated protein C.
Coagulation factor V and thrombophilia: background and mechanisms.
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
Deep vein thrombosis during administration of HMG for ovarian stimulation.
Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.
Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.
Detection of marked reduction of sensitivity to activated protein C prior to the onset of thrombosis during puerperium as detected by endogenous thrombin potential-based assay.
Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex.
Determining the crystal structure of fibrinogen.
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia.
Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
Dural sinus thrombosis associated with activated protein C resistance: MR imaging findings and proband identification.
Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects.
Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.
Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Endocardial Endothelial Dysfunction Progressively Disrupts Initially Anti then Pro-Thrombotic Pathways in Heart Failure Mice.
Engineering activated protein C to maximize therapeutic efficacy.
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.
Factor V A4070G (His1299Arg) mutation in Turkish pediatric patients with thrombosis.
Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.
Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C.
Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.
Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia.
Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.
Factor V Leiden is not common in children with portal vein thrombosis.
Factor V Leiden mutation and type 1 diabetes mellitus.
Factor V Leiden mutation in Turkish patients with homozygous cystathionine beta-synthase deficiency.
Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis.
Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
Familial coexistence of primary antiphospholipid syndrome and factor VLeiden.
Familial protein S deficiency presenting as deep vein thrombosis occurring during pregnancy.
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Familial thrombophilia: a complex genetic disorder.
Fatal pulmonary artery thrombosis in a patient with Behçet's disease, activated protein C resistance and hyperhomocystinemia.
Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Frequency of factor V Leiden mutation in Egyptian cases with myocardial infarction.
Functional properties of factor V and factor Va encoded by the R2-gene.
FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile.
Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution.
Generation and phenotypic analysis of protein S-deficient mice.
Generation of fibrinolytic activity by infusion of activated protein C into dogs.
Genetic analysis of factor V Leiden in a family with history of thrombosis and venous leg ulcers.
Genetic determinants of hemostasis phenotypes in Spanish families.
Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.
Haplotypes of the endothelial protein C receptor gene and Behçet's disease.
HELLP syndrome associated with factor V R506Q mutation.
Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification.
Heparin-induced thrombocytopenia and fatal thrombosis in a patient with activated protein C resistance.
Heparin-protein C interaction.
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis.
Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
Human activated protein C variants in a rat model of arterial thrombosis.
Human protein C and activated protein C Components of the human anticoagulation system.
Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries.
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.
Ile73Asn mutation in protein C introduces a new N-linked glycosylation site on the first EGF-domain of protein C and causes thrombosis.
Immunohistochemical expression of thrombomodulin in vestibular schwannoma.
In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach.
Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
Individual risk assessment of thrombosis in pregnancy.
Inherited resistance to activated protein C in a boy with multiple thromboses in early infancy.
Inherited Thrombophilia due to Factor V Leiden Mutation.
Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.
Inhibition of microarterial thrombosis by activated protein C in a rabbit model.
Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model.
Inhibition of transforming growth factor-? restores endothelial thromboresistance in vein grafts.
Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries.
Internal jugular vein thrombosis by protein C activated resistance.
Internal jugular vein thrombosis caused by resistance to activated protein C as a complication of ovarian hyperstimulation after in-vitro fertilization.
Intracardiac thrombus associated with resistance to activated protein C.
Intracardiac thrombus causing systemic embolism in a child with idiopathic ventricular tachycardia and heterozygous activated protein C resistance.
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
Ischemic colitis, pulmonary embolism, and right atrial thrombosis in a patient with inherited resistance to activated protein C.
Isolated cortical vein thrombosis and activated protein C resistance.
Issues concerning the laboratory investigation of inherited thrombophilia.
Kallikrein augments the anticoagulant function of the protein C system in thrombin generation.
Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
Laboratory evaluation of hypercoagulability.
Laboratory investigation of hypercoagulability.
Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant.
Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation.
Low doses of activated protein C delay arterial thrombosis in rats.
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals.
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Low prevalence of thrombophilic coagulation defects in patients with deep vein thrombosis of the upper limbs.
Lupus anticoagulants and thrombosis: the role of phospholipids.
Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).
Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S.
Mesenteric arterial thrombosis due to activated protein C resistance (factor V Leiden)
Mesenteric artery occlusion secondary to activated protein C resistance: a life-threatening combination.
Mesenteric vein thrombosis due to factor V Leiden gene mutation.
Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C.
Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Multi-chamber intracardiac thrombi associated with activated protein C resistance in a patient with dilated cardiomyopathy.
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors.
N-Terminal domain linkage modulates the folding properties of protein S epidermal growth factor-like modules.
Natural anticoagulants and the liver.
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
No association between thrombosis and factor V gene polymorphisms in Chinese Han population.
Non-catheter-related aortic thrombosis and resistance to activated protein C in a premature newborn.
Obstetric implications of the factor V leiden mutation: a review.
Oral contraceptives and thrombosis.
Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.
Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis.
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V.
Placental thrombosis and second trimester miscarriage in association with activated protein C resistance.
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers.
Plasma resistance to activated protein C in venous and arterial thrombosis.
Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
Platelet thromboembolism.
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease.
Postpartum seizures after epidural analgesia: a patient with a mutation of the factor V Leiden and prothrombin gene.
Predictors of left ventricular thrombus formation in patients with anterior myocardial infarction: role of activated protein C resistance.
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Predisposition to thrombosis by a factor V mutation causing hereditary resistance to activated protein C.
Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice.
Prevalence of activated protein C resistance (Factor V Leiden) in Lagos, Nigeria.
Prevalence of Factor V Genetic Variants Associated With Indian APCR Contributing to Thrombotic Risk.
Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.
Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S.
Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial.
Progressive gangrene of the hand following extravasation of antibiotics associated with hereditary resistance to activated protein C.
Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease.
Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
Protein C pathway impairment in nonsymptomatic cigarette smokers.
Protein C, isolation and potential use in prevention of thrombosis.
Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits.
Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis.
Pulmonary fibrosis is increased in mice carrying the factor V Leiden mutation following bleomycin injury.
Recombinant human activated protein C (Xigris).
Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.
Recombinant human activated protein C: current insights into its mechanism of action.
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Recurrent thrombosis in a patient with pseudohomozygous activated protein C resistance and homozygosity for MTHFR gene polymorphism C677T.
Recurrent thrombosis of the superior vena cava associated with activated protein C resistance: imaging findings.
Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.
Release and activity of histone in diseases.
Renal vein thrombosis in a newborn with prothrombotic genetic risk factors.
Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Resistance to activated protein C and digital thrombosis.
Resistance to activated protein C and FV leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.
Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.
Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S.
Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Resistance to activated protein C caused by a factor V gene mutation.
Resistance to activated protein C due to a factor V gene mutation The most common inherited risk factor of thrombosis.
Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Resistance to activated protein C in thalassaemic patients: an underlying cause of thrombosis.
Resistance to activated protein C in unselected patients with arterial and venous thrombosis.
Resistance to activated protein C in women using oral contraceptives.
Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Resistance to activated protein C: arterial thrombosis associated with autoimmune features.
Resistance to activated protein C: role in venous and arterial thrombosis.
Response to activated protein C during normal menstrual cycle and ovarian stimulation.
Retinal vascular occlusion and deficiencies in the protein C pathway.
Risk of Venous Thrombosis in Carriers of a Common Mutation in the Homocysteine Regulatory Enzyme Methylenetetrahydrofolate Reductase.
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice.
Role of the protein C pathway in the extraintestinal thrombosis associated with murine colitis.
Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Simple and rapid detection of factor V Leiden by allele-specific PCR amplification.
Soluble Endothelial Protein C Receptor and Coagulation Parameters as Prognostic Factors in Non-Small Cell Lung Cancer.
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Spontaneous thrombosis in mice carrying the factor V Leiden mutation.
Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate.
Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C.
Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
The 1691 G-->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients.
The antithrombotic effect of human activated protein C on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
The carbohydrate moiety of factor V modulates inactivation by activated protein C.
The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro.
The endothelial cell protein C receptor: its role in thrombosis.
The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients.
The factor V Leiden mutation is not a common cause of recurrent miscarriage.
The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome.
The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
The influence of factor VIII on measurement of activated protein C resistance.
The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey.
The response to activated protein C after cardiopulmonary bypass: impact of factor V leiden.
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo.
Therapeutic inhibition of thrombin activities, receptors, and production.
Three novel variants in the coagulation factor V gene associated with deep venous thrombosis in Chilean patients with Amerindian ethnic background.
Thrombophilia and fetal loss.
Thrombophilia and risk of venous thrombosis in patients with cancer.
Thrombophilia-associated pregnancy wastage.
Thrombosis in otherwise well children with the factor V Leiden mutation.
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss.
Utilization of testing for activated protein C resistance in a reference laboratory.
Vascular graft thrombosis secondary to activated protein C resistance: a case report and literature review.
Venous gangrene of the upper extremity.
Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation.
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Venous thrombosis in a replanted finger with underlying factor V Leiden mutation.
What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease?
Whole blood clot lysis: in vitro modulation by activated protein C.
[A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506-->Gln mutation of the gene of factor V]
[A newly discovered blood coagulation disorder. Resistance to activated protein C as a cause of thrombosis]
[Acquired resistance to activated protein C in pregnancy]
[Activated protein C resistance in Behçet disease]
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis]
[Activated protein C resistance: role in venous and arterial thrombosis]
[Antiphospholipid thrombosis syndrome and acquired activated protein C resistance]
[APC (activated protein C) resistance and oral contraceptives]
[APC resistance. Resistance against activated Protein C, a frequent cause of congenital thrombosis susceptibility]
[Application of recombinant human activated protein C with blood product administration and deep vein thrombosis in severe sepsis]
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
[Clinical management of patients with sepsis]
[Clinical usefulness of global assays of the anticoagulant pathway of protein C]
[Congenital deficiencies of natural anticoagulant systems responsible for recurrent thromboembolism]
[Deep venous thrombosis in pregnant women]
[Effects of low doses of activated protein C in experimental arterial thrombosis in rats]
[Incidence and risk factors for venous thromboembolism]
[Inherited thrombophilia]
[Inhibitory effect of activated protein C and heparin on arterial thrombosis]
[Laboratory identification of blood hypercoagulability]
[Mesenteric and splenic vein thrombosis in a female patient with essential thrombocytosis and activated protein C resistance]
[Point mutation G-->A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C]
[Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis]
[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]
[Resistance to activated protein C by mutation of the factor V gene. Most frequent blood coagulation defect in venous thromboses]
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
[Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations]
[Resistance to activated protein C. A common genetic risk factor in venous thrombosis]
[Retinal vein occlusion and resistance to activated protein C]
[Role of the hemostasis laboratory in the etiologic approach to deep vein thrombosis]
[Study of activated protein C resistance(APC-R) and FV Leiden in healthy blood donors and patients with thrombosis]
[The numerous properties of the anticoagulant protein C]
[Thrombophilia in systemic lupus erythematosus: A case-control study].
[Thrombophilic states]
[Thrombosis risk in activated protein C resistance deficiency?]
Thrombotic Microangiopathies
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Thyroid Cancer, Papillary
Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma.
Tuberculosis
A thrombomodulin mutation that impairs activated protein C generation results in uncontrolled lung inflammation during murine tuberculosis.
Brief report: tuberculosis sepsis and activated protein C.
The endothelial protein C receptor and activated protein C play a limited role in host defense during experimental tuberculosis.
Urinary Tract Infections
Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report.
Uveitis, Posterior
Haplotypes of the endothelial protein C receptor gene and Behçet's disease.
Vascular Diseases
Genetic thrombophilia in patients with retinal vascular occlusion.
Homocysteine and human reproduction.
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Retinal vascular occlusion and deficiencies in the protein C pathway.
Vascular System Injuries
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Engineering activated protein C to maximize therapeutic efficacy.
Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Vasospasm, Intracranial
Inhibitory effect of activated protein C on cerebral vasospasm after subarachnoid hemorrhage in the rabbit.
Venous Insufficiency
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
Venous Thromboembolism
?2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:?2M Levels Are Associated with Venous Thromboembolism.
A case control study of deep venous thrombosis in relation to factor V G1691A (Leiden) and A4070G (HR2 Haplotype) polymorphisms.
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.
A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
A monoclonal antibody to human protein S used as the capture antibody for measuring total protein S by enzyme immunoassay.
A Rapid Activated Protein C Sensitivity Test as a Diagnostic Marker for a Suspected Venous Thromboembolism in Pregnancy and Puerperium.
Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels.
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism.
Activated protein C resistance (FV:Q506) and pregnancy.
Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.
Activated protein C resistance, factor V Leiden and peripheral vascular disease.
Activated protein C resistance--a major risk factor for thrombosis.
Activated protein C resistance: from phenotype to genotype and clinical practice.
Activated protein C resistance: the most common risk factor for venous thromboembolism.
Age as a risk factor for myocardial infarction in Leiden mutation carriers.
An underestimated combination of opposites resulting in enhanced thrombotic tendency.
Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
APC resistance in neonates and infants: adjustment of the APTT-based method.
Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C.
Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R.
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer.
Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk.
Cleaved protein S (PS), total PS, free PS, and activated protein C cofactor activity as risk factors for venous thromboembolism.
Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred.
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Development and application of an automated chromogenic thrombin generation assay that is sensitive to defects in the protein C pathway.
Diminished response to activated protein C is not correlated with severity of peripheral arterial occlusive disease.
DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Effects of oral contraceptives on hemostasis and thrombosis.
Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance.
Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
Factor V Leiden and hemophilia.
Factor V Leiden and post thromboembolic pulmonary hypertension.
Factor V Leiden and pulmonary embolism in a young woman taking an oral contraceptive.
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Factor V Leiden thrombophilia.
Factor V variants, activated protein C resistance and venous thromboembolism.
Factor V:Q506 mutation-resistance to activated protein C (APC): clinical implications with respect to family screening.
FV-ARG-506-GLN-Mutation-associated resistance to activated protein C in ischemic stroke.
Heritability of plasma concentrations of activated protein C in a Spanish population.
Hormonal influences on hemostasis in women.
Incidence of factor V Leiden in patients with acute myocardial infarction.
Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism.
Intraindividual consistency of the activated protein C resistance phenotype.
Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?
Laboratory testing for hypercoagulable disorders.
Low level of circulating activated protein C is a risk factor for venous thromboembolism.
Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation.
No association of APC resistance with myocardial infarction.
Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism.
Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: relationships with plasma homocysteine levels.
Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
Prevalence of APC resistance and its relationship to arterial and venous thromboembolism in a general population sample of elderly Swedish men: The Study of Men Born in 1913.
Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.
Prevalence of the Factor V E666D Mutation and Its Correlation With Activated Protein C Resistance in the Chinese Population.
Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations.
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.
Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia--the need for a prospective multicentre study.
Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.
Resistance to activated protein C and digital thrombosis.
Resistance to activated protein C and ischemic arterial disease in a young man.
Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
Resistance to activated protein C as pathogenic factor of venous thromboembolism.
Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.
Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study.
Role of activated protein C resistance in left atrial thrombogenesis in patients with mitral stenosis.
Soluble Endothelial Protein C Receptor and Coagulation Parameters as Prognostic Factors in Non-Small Cell Lung Cancer.
The association between extrinsic activated protein C resistance and venous thromboembolism in women.
The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).
The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype.
Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
[Activated protein C resistance--a recently discovered hereditary thrombophilia]
[Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism]
[Brain stem ischemia in a boy with resistance to C activated protein and elevated lipoprotein A]
[Diagnosis of thrombophilia based on coagulation and genetic studies]
[Laboratory testing for venous thromboembolism]
[Pulmonary embolism. Risk factors of venous thromboembolic disease]
[The significance of APC resistance (activated protein C) for clinical practice]
[Thrombophilic states]
[Venous branch occlusion due to APC resistance]
Venous Thrombosis
A case of deep vein thrombosis in idiopathic nephrotic syndrome with resistance to activated protein C.
A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.
A single genetic origin for a common Caucasian risk factor for venous thrombosis.
Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis.
Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
Acquired APC resistance in neurosurgical patients may not be a risk factor for postoperative deep vein thrombosis.
Activated protein C (APC) resistance in indian juvenile deep vein thrombosis (DVT)
Activated protein C levels in Behçet's disease and risk of venous thrombosis.
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis.
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Activated protein C resistance as a "new" cause of deep venous thrombosis in aviators.
Activated protein C resistance as a basis for venous thrombosis.
Activated protein C resistance caused by a common factor V mutation has a single origin.
Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.
Activated protein C resistance due to factor V Leiden, elevated coagulation factor VIII and postoperative deep vein thrombosis in late breast reconstruction with a free TRAM flap: a report of two cases.
Activated protein C resistance during in vitro fertilization treatment.
Activated protein C resistance in a neonate with venous thrombosis.
Activated protein C resistance in deep venous thrombosis.
Activated protein C resistance in deep-vein thrombosis.
Activated protein C resistance in pediatric inflammatory bowel disease.
Activated protein C resistance in venous thrombosis.
Activated protein C resistance--a major risk factor for thrombosis.
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion.
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation.
Activated protein C resistance: What have we learned now that the dust has settled?
An assessment of the comparative utility of functional and molecular level analyses in the investigation of patients with thrombophilia.
Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?
Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients.
Are MPNs Vascular Diseases?
Arg506Gln mutation of the coagulation factor V gene not detected in Japanese pulmonary thromboembolism.
Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance.
Association of increased fibrinogen concentration with impaired activation of anticoagulant protein C.
Association of resistance to activated protein C and dural arteriovenous fistulas.
Atypical presentation of livedo racemosa in a factor V Leiden heterozygous positive patient with Pseudomonas aeruginosa urosepsis.
Bilateral renal venous thrombosis in a neonate associated with resistance to activated protein C.
Central retinal vein thrombosis associated with resistance to activated protein C.
Cerebral venous thrombosis and activated protein C resistance.
Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation.
Changes in the plasma levels of protein C system parameters in pregnancy.
Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V.
Circulating activated protein C in subjects with heterozygous Gln506-factor V.
Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis.
Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression.
Coagulation factor V Leiden mutation in sudden fatal pulmonary embolism and in a general northern European population sample.
Combined genetic defect (homogeneity for factor V Leiden and heterogeneity for prothrombin G20210A allele), in a young patient, with recurrent deep vein thrombosis and serious postphlebitic syndrome--a case report.
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis.
Congenital and acquired activated protein C resistance.
Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide.
Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance.
Detection of factor V Leiden in Thai patients with venous thrombosis.
Determinants of the APTT- and ETP-based APC sensitivity tests.
Diagnostic algorithm for thrombophilia screening.
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke.
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Factor V and protein S as cofactors to activated protein C.
Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Factor V Leiden (FVQ 506) is common in a Brazilian population.
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage.
Factor V Leiden and its relation to left ventricular thrombus in acute myocardial infarction.
Factor V Leiden in patients with venous thrombosis in Slovak population.
Factor V Leiden mutation and its relation to left atrial thrombus in chronic nonrheumatic atrial fibrillation.
Factor V Leiden mutation and type 1 diabetes mellitus.
Factor V Leiden mutation in a case with ischemic stroke: which relationship? A case report.
Factor V Leiden mutation in cerebral venous thrombosis.
Factor V Leiden mutation is associated with ocular involvement in Behçet disease.
Factor V Leiden prevalence in venous thromboembolism patients.
Factor V Leiden: a disorder of factor V anticoagulant function.
Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis?
Factor V Leiden: who should be tested?
Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.
Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome.
Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls.
Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection.
Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus.
Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Fibrinogen ?' increases the sensitivity to activated protein C in normal and factor V Leiden plasma.
Frequency of a defective response to activated protein C in patients with a history of venous thrombosis.
Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens.
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis.
High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice.
Homozygous hereditary resistance to activated protein C presenting as cerebral venous thrombosis.
Hypercoagulability in various autoimmune diseases: no association with factor V Leiden mutation.
Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis.
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
Increased risk of venous thrombosis by AB alleles of the ABO blood group and Factor V Leiden in a Brazilian population.
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
Inherited resistance to activated protein C, a major basis of venous thrombosis, is caused by deficient anticoagulant cofactor function of factor V.
Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
Inherited thrombotic disorders: an update.
Iron-deficiency anaemia in childhood: a risk factor for severe venous thrombosis?
Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C.
Leiden mutation in patients with Crohn's disease.
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis 4 years after transplant.
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism.
Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C.
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.
Mutations at the activated protein C cleavage sites Arg336 and Arg562 of factor VIII in Thai patients with venous thrombosis.
New concepts in coagulation.
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study.
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Parameters predicting complications in flap surgery.
Patients with persistent APC-resistance without factor V Leiden mutation.
Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis.
Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers.
Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C.
Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation.
Prevalence of common thrombophilia markers and risk factors in Indian patients with primary venous thrombosis.
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
Prevalence of factor V Leiden mutation in various populations.
Primary thrombophilia in Saudi Arabia.
Protein C antigen levels in major abdominal surgery: relationships to deep vein thrombosis, malignancy and treatment with stanozolol.
Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.
Prothrombotic Factors Have Significant Association with Arterial and Venous Strokes in Indian Tamilians.
Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.
Raised factor VIII is associated with coronary thrombotic events.
Rapid detection of factor V Leiden (FVQ506) by non-radioactive single strand conformation polymorphism (SSCP).
Rapid multiplex analysis for the factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia.
Recurrent deep-vein thrombosis based on homozygous factor V Leiden mutation acquired after liver transplantation.
Recurrent venous thrombosis despite correction of activated protein C resistance following orthotopic liver transplantation.
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.
Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
Resistance to activated protein C activity of an anti-beta 2-glycoprotein I antibody in the presence of beta 2-glycoprotein I.
Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.
Resistance to activated protein C as a basis for venous thrombosis.
Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome.
Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
Resistance to activated protein C due to factor V R506Q mutation as a cause of venous thrombosis.
Resistance to activated protein C in healthy women taking oral contraceptives.
Resistance to activated protein C in unselected patients with arterial and venous thrombosis.
Resistance to activated protein C in women using oral contraceptives.
Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
Resistance to activated protein C: a common anticoagulant deficiency in patients with venous leg ulceration.
Resistance to activated protein C: a common inherited cause of venous thrombosis.
Resistance to activated protein C: a major cause of inherited thrombophilia.
Resistance to activated protein C: role in venous and arterial thrombosis.
Retinal vascular occlusion and deficiencies in the protein C pathway.
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.
Role of Gly197 in the structure and function of protein C.
Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden.
Sensitivity to activated protein C in patients with deep vein thrombosis during early puerperium period.
Signal transduction induced by activated protein C: no role in protection against sepsis?
Significantly increased prevalence of factor V Leiden in patients with dural arteriovenous fistulas.
Spontaneous central vein thrombosis in a patient with activated protein C resistance and dengue infection: An association or causation?
Subacute liver failure induced by phenprocoumon treatment.
Successful liver transplantation in a patient with Budd-Chiari syndrome caused by homozygous factor V Leiden.
Successful management of a pregnant woman with heterozygous protein C deficiency using activated protein C concentrate.
Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C.
Surrogate end points in clinical research: hazardous to your health.
Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature.
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease.
The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis.
The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka.
The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance.
The Prevalence of Activated Protein C Resistance and F V Leiden in Healthy Population of Edirne, Turkey.
The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese.
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C.
The role of activated protein C resistance in the pathogenesis of venous thrombosis.
Three-year evaluation of late breast reconstruction with a free transverse rectus abdominis musculocutaneous flap in a county hospital in Sweden: a retrospective study.
Thrombin generation in clinical conditions.
Thromboembolic disease and present oral contraception.
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
Thrombophilia as a multigenic disease.
Thrombophilic mechanisms of OCs.
Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss.
Use of first nucleotide change technology to determine the frequency of factor V Leiden in a population of Australian blood donors.
Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies.
Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient.
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.
Venous thrombosis revisited.
Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor.
[A new cause of hereditary venous thrombosis: activated protein C resistance]
[A new hereditary cause of portal vein thrombosis: the abnormal resistance to activated protein C by the Arg 506-->Gln mutation of the gene of factor V]
[Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population]
[Activated protein C resistance and deep venous thrombosis in pregnancy]
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]
[Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group]
[Activated protein C resistance in patients with venous leg ulcer]
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis]
[Activated protein C resistance: role in venous and arterial thrombosis]
[Application of recombinant human activated protein C with blood product administration and deep vein thrombosis in severe sepsis]
[Chronic abdominal pain due to bowel ischemia in a patient with Leiden factor V mutation]
[Clinical management of patients with sepsis]
[Deep venous thrombosis in pregnant women]
[Effects of factor V Leiden mutations on prognosis in patients with acute myocardial infarction]
[Factor V Leiden mutation leads to enhanced atherosclerosis in apolipoprotein E deficient mice]
[G20210A transition in the prothrombin gene and venous thromboembolic disease]
[Hereditary disorders of the protein C system in central artery and branch arteriolar occlusions]
[Oral contraceptives and activated protein C resistance: a paradigmatic example of genotype and environment interaction in the development of deep venous thrombosis]
[Protein S-Specific Activity as an Indicator of Thrombophilia].
[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]
[Resistance to activated protein C by mutation of the factor V gene. Most frequent blood coagulation defect in venous thromboses]
[Resistance to activated protein C disclosed by postphlebitic disease. Two cases]
[Resistance to activated protein C. A common genetic risk factor in venous thrombosis]
[Retinal vein occlusion and resistance to activated protein C]
[The role of resistance to C active protein (R-APC) in a pediatric stroke]
Ventilator-Induced Lung Injury
Effects of Activated Protein C on Ventilator-Induced Lung Injury in Rats.
Inhaled activated protein C protects mice from ventilator-induced lung injury.
Virus Diseases
Coagulopathies and osteonecrosis.
RACK1 is indispensable for porcine reproductive and respiratory syndrome virus replication and NF-?B activation in Marc-145 cells.
Systemic host inflammatory and coagulation response in the Dengue virus primo-infection.
Voltage-Dependent Anion Channel Protein 2 (VDAC2) and Receptor of Activated Protein C Kinase 1 (RACK1) Act as Functional Receptors for Lymphocystis Disease Virus Infection.
[Epidemiological risk factors for non-traumatic osteonecrosis]